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1 Introduction 
Type 1 diabetes is a chronic disease characterized by deficient insulin secretion due to 
the loss of insulin-producing beta cells in the endocrine pancreatic islets. The disease 
remains subclinical until the number of beta cells is too low to produce the amount of 
insulin needed to maintain glucose homeostasis, resulting in symptoms of 
hyperglycaemia, such as polyuria and polydipsia with associated weight loss. Although 
the disease may manifest itself at any age, it has been estimated that about half of the 
patients are diagnosed during childhood or adolescence, making diabetes one of the 
most common severe chronic diseases of childhood in industrialized countries.  
The incidence of childhood-onset type 1 diabetes appears to be increasing in 
developed countries, for unknown reasons. The most rapid increase has been seen 
among young children. Although the prognosis for a child with diabetes has improved 
substantially over the last two decades, the manifestation of an incurable lifelong 
disease with an absolute need for exogenous insulin replacement and the awareness of 
the potential severe long-term complications do present a challenge to the child’s 
normal physical, mental and social development. The disease places an extra burden on 
the whole family of the affected child, and also on society at large, putting extra 
pressure on health care resources. Therefore there is a great interest in understanding 
how the disease is initiated, in the hope that it could eventually be prevented.  
Overt type 1 diabetes is preceded by an asymptomatic preclinical period 
characterized by the presence of markers of beta-cell autoimmunity which are closely 
associated with progressive destruction of the insulin-producing beta cells. Although 
the subjects most likely to develop the disease can be identified, prediction on an 
individual level is still uncertain and no specific characteristics that could completely 
discriminate the subjects en route to clinical type 1 diabetes have been identified so far. 
Several intervention trials aimed at preventing or delaying the development of type 1 
diabetes at the stage of asymptomatic autoimmunity have been initiated during the last 
decade. As these use clinical disease as the endpoint, they have to be large and of long 
duration. Therefore there is an urgent need to establish additional surrogate markers by 
which the subjects with the highest risk of developing clinical disease could be 
identified and by which the effects of intervening in the autoimmune process could be 
assessed.  
The immunological mechanisms underlying human type 1 diabetes are still not 
fully understood, although there is strong evidence to suggest that autoreactive T cells 
are major players in the pathogenic process. A crucial aspect of endocrine 
autoimmunity is why and how lymphocytes migrate from the primary lymphoid tissue 
to their targets. This migration is controlled in part by selective expression of cell 
adhesion molecules on the surface of the lymphocytes and vascular endothelial cells. 
These ”sticky” molecules also participate in various other immune reactions thought to 
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be involved in the process of autoimmunity. It is now well established that soluble 
isoforms of the cell adhesion structures can be found in the peripheral circulation. The 
detection of increased levels of these soluble molecules in various inflammatory 
conditions has led to the hypothesis that they could serve as markers of disease activity, 
or that they may play a role in the disease process.  
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2 Review of the literature 
2.1 Adhesion molecules 
Cell adhesion molecules are cell surface proteins that are critical for many normal 
physiological processes; they allow cells to interact and communicate with each other 
and their environment and, in doing so, regulate a range of cell functions. In the 
immune system they not only mediate the migration and ”homing” of lymphocytes to 
specific tissues but they are also involved in many cell-to-cell interactions that control 
immune responses. Given their widespread distribution, it is not surprising that cell 
adhesion molecules have been implicated in many diverse pathological processes, such 
as the initiation and propagation of autoimmune diseases. A large repertoire of 
adhesion molecules and their combinations may potentially create conditions for 
selective and closely targeted action at different sites and tissues in the body. 
2.1.1 Classification 
Adhesion molecules that are important in leukocyte interactions can be classified into 
three major groups on the basis of their structure and certain common properties: 
selectins, integrins and members of the immunoglobulin supergene family (Table 1). 
Cell adhesion molecules bind to other cells or matrix components through interaction 
with appropriate counter-receptors, referred to as ligands. In some cases the ligands are 
themselves adhesion molecules, as is the case with integrin family whose ligands are 
members of the immunoglobulin superfamily, and vice versa.  
Selectins are glycoproteins, and these may be subclassified according to the cell 
type on which they were originally identified: L-selectin (leukocytes), P-selectin 
(platelets/endothelium) and E-selectin (endothelium). Their common structural 
component is a lectin domain which is critical for ligand-binding to sialyl-Lewisx -like 
cell surface carbohydrates. The most important receptors are sialylated, fucosylated 
glycoproteins P-selectin glycoprotein ligand 1 (PSGL-1), E-selectin ligand 1 (ESL-1) 
and mucin-like vascular addressins, such as mucosal addressin-cell adhesion molecule 
1 (MAdCAM-1) and peripheral node addressin (PNAd). The differential expression of 
vascular addressins on the high endothelial venules (HEVs) in lymph nodes and 
Peyer’s patches regulates differential trafficking of lymphocyte subsets. All selectins 
are constitutively active and rapidly shed on activation. L-selectin (CD62L) is 
expressed on all leukocytes (reviewed by von Andrian and Mackay 2000), including all 
naïve lymphocytes and a subpopulation of memory cells which share the same 
recirculatory pattern as naïve lymphocytes (Sallusto et al. 1999). P-selectin (CD62P) is 
 10 
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found on endothelial cells and activated platelets, and E-selectin (CD62E) is an 
endothelial selectin, the in vivo expression of which is mainly seen on activated 
endothelium, as in inflammatory disorders of the skin and airway (Groves et al. 1991, 
Gundel et al. 1991).  
Integrin adhesion molecules are cell surface proteins that integrate extracellular 
information into the cytoskeleton. They are heterodimeric, transmembrane structures 
composed of non-covalently bound α and β subunits. Integrins are named according to 
the composition of their constituent α and β protein chains, which are identified by a 
number or letter. They are expressed on various types of cells, and most cells express 
different integrins. Integrins bind to a variety of extracellular matrix proteins, e.g. 
laminin, collagen and receptors of the immunoglobulin superfamily (reviewed by 
Hynes 1992). α4β1, also known as very late activation antigen 4 (VLA-4), and α4β7 are 
expressed on most leukocytes except neutrophils. Up-regulated expression of α4β1 is 
seen on effector and memory cells, while enhanced expression of α4β7 is seen on gut-
homing effector and memory cells (von Andrian and Mackay 2000). 
Adhesion molecules of the immunoglobulin superfamily includes a variety of cell 
surface molecules that are classified together because each molecule carries 
immunoglobulin domains repeated a variable number of times in its extracellular part. 
The immunoglobulin superfamily includes molecules such as major histocompatibility 
complex (MHC) class I and II molecules, intercellular adhesion molecules 1, 2 and 3, 
i.e. ICAM-1 (CD54), ICAM-2 (CD102) and ICAM-3 (CD50), vascular cell adhesion 
molecule 1 (VCAM-1, CD106), platelet endothelial cell adhesion molecule 1 
(PECAM-1, CD31) and MAdCAM-1, in addition to the classical immunoglobulins 
produced by B lymphocytes. The expression of intercellular adhesion molecules is 
constitutive and there is hardly any change in expression levels after induction, with the 
exception of ICAM-1, which is expressed on a variety of cell types, including 
endothelial cells, where it serves as an important counter-receptor for leukocyte 
integrins. Exposure to interleukin 1 (IL-1), tumour necrosis factor α (TNF-α) and 
interferon γ (IFN-γ) at least results in augmented cell surface expression of ICAM-1 
(Rothlein et al. 1988, reviewed by Springer 1990 and Carlos and Harlan 1994). The 
RNA and protein synthesis induced by inflammatory mediators has been shown to be a 
fairly slow process, as marked changes were not seen until 12 hours after stimulation 
(Dustin et al. 1986). ICAM-2 is expressed on endothelial cells and platelets, and 
ICAM-3 on resting leukocytes (Fawcett et al. 1992). MAdCAM-1 expression on high 
endothelial venules in gut-associated lymphoid tissue mediates the homing of 
lymphocytes to Peyer’s patches and mesenteric lymph nodes (Streeter et al. 1988). The 
predominant ligand of MAdCAM-1 is the α4β7 integrin, but L-selectin has also been 
shown to bind this molecule (Berg et al. 1993).The expression of MAdCAM-1 on 
postcapillary venules of mucosal lymphoid tissue appears to be constitutive, but 
enhanced expression has been demonstrated on cultured endothelial cells by means of 
inflammatory mediators such as TNF-α (Sikorski et al. 1993). VCAM-1 expression is 
seen on all endothelial cells and on certain leukocytes, although its major functional 
expression sites are HEVs in the lymph nodes (reviewed by Salmi and Jalkanen 1997). 
PECAM-1 is expressed on the endothelium of the vasculature and on some leukocytes. 
It plays an important role in monocyte transmigration and probably contributes to 
additional leukocyte adhesion in general (reviewed by Bianchi et al. 1997). 
Table 1. Selectins, integrins and members of the  immunoglobulin superfamily with a role in T-cell  migration, 
Adhesion molecule 
(alternative  name) 
Distribution Regulation of function and 
expression 
Ligands Role in T-cell migration  
 
Selectins   All selectins are constitutively active Sialyl-Lewisx-like 
sugars  
 
     
L-selectin (CD62L) All naïve lymphocytes and 
a subpopulation of memory 
cells 
Rapidly shed on activation PNAd, PSGL-1, 
MAdCAM-1, E-
selectin, GlyCAM-1, 
CD34 
Homing to lymph nodes and Peyer’s 
patches 
     
     
E-selectin (CD62E) Endothelial cells  Induced by TNF-α, IL-1, endotoxin CLA, L-selectin, 
PSGL-1, ESL-1 
Homing of memory and effector cells to 
skin and sites of inflammation 
 
 
     
     
P-selectin (CD62P) Endothelial cells, platelets Stored intracellularly in resting cells, 
rapid surface translocation 
stimulated by histamine, for 
example 
PNAd, PSGL-1 Homing of memory or effector (Th1) 
cells to the site of inflammation 
 
     
β2 Integrins     
     
     
αLβ2 (LFA-1, 
CD11aCD18) 
All leukocytes  Enhanced expression on effector and 
memory cells 
ICAM-1,2,3 Homing of all lymphocytes to lymph 
nodes, Peyer’s patches and sites of 
inflammation; adhesion to antigen-
presenting cells 
 
αMβ2 (Mac-1, 
CD11bCD18) 
Myeloid cells, some 
activated T cells 
Rapid up-regulation on activated 
myeloid cells 
ICAM-1, factor X, 
fibrinogen, C3b 
 
Unknown 
αxβ2 (p150,95, 
CD11cCD18) 
Dendritic cells  Constitutive expression Fibrinogen, C3b Unknown 
αDβ2 (CD11dCD18) Monocytes, macrophages, 
eosinophils 
High levels of expression on foam 
cells in intimal plaques 
VCAM-1, ICAM-1 and 
3 
Unknown 
 
α4  Integrins     
α4β1 (VLA-4) Most leukocytes except 
neutrophils  
Enhanced expression on effector and 
memory cells 
fibronectin, VCAM-1, 
α4 integrin 
Homing of memory and effector cells to 
inflamed  tissue, especially lung 
 
α4β7 Lymphocytes, natural killer 
cells, mast cells, basophils, 
monocytes 
Enhanced expression on gut-homing 
effector and memory cells 
MAdCAM-1, 
fibronectin, (VCAM-1) 
Homing of all lymphocytes to gut and 
associated lymphoid tissue 
 
Immunoglobulin 
superfamily 
 
    
ICAM-1 (CD54) Most types of cells Up-regulated by lipopolysaccharide 
and inflammatory cytokines 
αLβ2 and αMβ2  
integrins, fibrinogen 
Critical endothelial ligand for β2 
integrins 
 
ICAM-2 (CD102) Endothelial cells, platelets  Constitutive expression, no change 
in level of expression during 
inflammation 
αLβ2 integrin Unknown 
VCAM-1 (CD106) Endothelial cells, bone 
marrow stroma, follicular 
dendritic cells, osteoblasts, 
mesothelium 
 
Absent on most resting endothelial 
cells, induced by cytokines 
α4β1, α4β7 and αDβ2 
integrins 
Homing of memory and effector cells to 
inflamed tissue 
 
MAdCAM-1 HEVs in gut-associated 
lymphoid tissue and sites 
of chronic inflammation, 
lamina propria, spleen 
Constitutive expression in HEVs, 
induced in insulitis, thymic 
hyperplasia, some forms of arthritis 
α4β7 integrin, L-
selectin  
Homing of all lymphocytes to gut and 
associated lymphoid tissue 
 
     
 
C3b complement 3b, CLA cutaneous lymphocyte antigen, GlyCAM-1 glycosylation-dependent cell-adhesion molecule 1, Mac-1 macrophage antigen 1, 
p150,95 protein with 150 kDa and 95 kDa subunits (modified from von Andrian and Mackay 2000) 
 
 
 
 
2.1.2 Functional aspects 
The interactions of the adhesion molecules in adaptive immune responses culminate in three important 
cellular functions: lymphocyte homing to lymphoid tissues and to inflammatory sites, and co-stimulation 
of cellular activation. Most adhesion molecules play fairly broad roles in the generation of immune 
responses. While the mechanisms underlying migration and homing are similar and fairly well 
characterized, those involved in cellular activation are, as yet, incompletely delineated. Through their 
expression on lymphoid and non-lymphoid tissues, adhesion molecules may be involved in the initiation 
and propagation of the disease processes in many organ-specific autoimmune/inflammatory disorders, 
which from the histopathological point of view are characterized by lymphocytic infiltration in the target 
tissues. These include type 1 diabetes. 
2.1.2.1 Lymphocyte homing 
Lymphocyte homing can be perceived as a specific, regulated cascade characterized by four distinct 
phases, each involving different sets of adhesion molecules. As each step involves a large number of 
adhesion molecules and endothelial counter-receptors, the number of interactive combinations is high. 
The initial contact made by lymphocytes with the endothelial cells is called tethering, and this is 
followed by a firmer contact, ”rolling”, if there are strong enough interacting ligands at the site. 
Tethering and rolling are almost exclusively properties of selectins, although α4 integrins may 
contribute. Rolling is followed by the activation of integrins mediated by chemokines, which are small 
cytokine-like chemotactic molecules released from the tissue, resulting in firm adhesion. Subsequently 
the lymphocytes undergo changes in shape in order to be able to transmigrate through the junctions 
between the endothelial cells towards the site of highest concentration of the inflammatory chemokines 
released by the target tissue at a site of inflammation (von Andrian and Mackay 2000). 
The first event in an adaptive immune response is homing of naïve T cells to lymph nodes and 
Peyer´s patches. L-selectin was originally known as a peripheral lymph node (PLN) homing receptor, 
since blocking of its function prevents the homing of lymphocytes to peripheral lymph nodes. L-selectin 
also mediates binding to gut-associated lymphoid tissue (Hamann et al. 1991) and to the activated 
endothelium of extra-lymphoid tissue (Dawson et al. 1992, Ley et al. 1993). The preferred site of 
migration from the blood to the lymphoid tissues is through vessels with the morphology of high 
endothelial venules, although leukocyte migration may occur across any endothelial cell barrier. HEVs 
are composed of specialized postcapillary venules of a kind found in all secondary lymphoid tissues or 
inflamed non-lymphoid tissues that support high levels of lymphocyte import from the blood (reviewed 
by Girard and Springer 1995). Peripheral node addressins are expressed on HEVs in lymph nodes, while 
mucosal Peyer’s patch and lactating mammary gland HEVs express MAdCAM-1 (reviewed by Springer 
1994, Girard and Springer 1995). L-selectin binds both of these addressins, while binding of α4β7 
integrin to MAdCAM-1 is needed to maintain rolling in Peyer’s patches. Gut-homing effector cells 
expressing high levels of α4β7 integrin attach directly to MAdCAM-1, whereas naïve T cells preferably 
engage L-selectin first and then MAdCAM-1. Lymphocyte function-associated antigen 1 (LFA-1), 
which is highly expressed on all normal lymphocytes, is the most important integrin mediating 
lymphocyte homing, and ICAM-1 and ICAM-2 are the principal ligands involved in LFA-1-mediated 
firm adhesion of lymphocytes to the endothelium (von Andrian and Mackay 2000).  
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The best-understood tissue-selective homing pathways are those in the skin and intestine (reviewed 
by Butcher and Picker 1996 and by Robert and Kupper 1999), but there may be other selective migration 
streams, such as to the lungs, joints and central nervous system. Antigen-experienced T cells often 
display a tissue specificity that may improve their chances of re-encountering an antigen, and the 
differential expression of adhesion molecules can direct different subsets of effector T cells to specific 
sites. Thus T cells that have been exposed to cutaneous pathogens in skin-draining lymph nodes express 
cutaneous lymphocyte antigen (CLA) and migrate preferentially to the skin, whereas effector cells that 
arise in Peyer’s patches in response to enteroviral infections are most useful in the gut, expressing 
considerable levels of α4β7 integrin. The ligands of the latter two molecules are E-selectin, which is 
present on the skin venule endothelium, and MAdCAM-1, found on the gut lamina propria HEVs, 
respectively. Effector T cells that recognize antigens in tissues produce cytokines, such as TNF-α, which 
further activate endothelial cells to express E-selectin, VCAM-1 and ICAM-1. Enhanced expression of 
ICAM-1 and VCAM-1 on endothelial cells will bind VLA-4 and LFA-1 on effector T cells, recruiting 
more of these cells into tissues that house the antigen. Monocytes are recruited to the site by binding to 
E-selectin.  
2.1.2.2 Aspects of lymphocyte activation 
While migrating through the cortical region of the lymph node to become activated, the naïve T cell 
recognizes a foreign or a native peptide bound to a MHC molecule and binds transiently to the antigen-
presenting cell that it encounters. Cell surface molecules of the immunoglobulin superfamily are 
important for the interactions of lymphocytes with antigen-presenting dendritic cells: ICAM-1 and 2, 
LFA-3 and also a dendritic cell receptor DC-SIGN (CD209), a recently discovered lectin, on antigen-
presenting cells interact with CD2, LFA-1 and ICAM-3 on naïve T cells. The precise role of each 
molecule has been difficult to delineate, perhaps due to synergies in the functioning of different cell 
adhesion molecules. There seems to be enough redundancy in the molecules mediating adhesive T-cell 
interactions to enable immune responses to occur in the absence of any one of them (Janeway et al. 
2001a).  
Naïve (pre-antigen encounter) lymphocytes home to lymph nodes through the binding of L-selectin 
to sulphated carbohydrates, while memory lymphocytes tend to return to the environment in which they 
first encountered the antigen, which results in preferential trafficking to non-lymphoid tissues and 
inflammatory lesions. This dichotomy results from the differential expression and activation of 
lymphocyte cell surface adhesion molecules which occurs during the naïve-memory transition. After 
having encountered an antigen, naïve T cells differentiate into antigen-specific armed effector T cells, 
and many lose expression of L-selectin during this process, while expression of α4β1 integrin and LFA-1 
are enhanced. These molecules bind to VCAM-1 and ICAM-1 on peripheral vascular endothelial cells at 
sites of inflammation and this binding helps in the extravasation of the effector T cells. Memory T cells 
share the surface characteristics of activated armed effector T cells (Janeway et al. 2001b).  
The effector T-cell interactions with target cells are initiated by antigen-non-specific cell adhesion 
molecules. The initial binding of an armed effector T cell to its target, like that of a naïve T cell to an 
antigen-presenting cell, involves non-specific adhesion molecules. The major initial interaction occurs 
between LFA-1 on the T cell and ICAM-1 or 2 on the target cell. This allows the T cell to remain in 
contact with the target cell and to scan its surface for the presence of MHC complexes. Effector T cells 
that recognize pathogenic antigens in the tissues produce cytokines such as TNF-α, which activates 
endothelial cells to express E-selectin, VCAM-1 and ICAM-1. These can then act on effector cells to 
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activate their adhesion molecules, and the presence of interactive adhesion molecules facilitates the 
recruiting of more effector T cells to the tissue that houses the antigen. At the same time monocytes are 
recruited to these sites by adhesion to E-selectin. Thus one or a few specific effector T cells 
encountering an antigen in a tissue can initiate a potent local inflammatory response that recruits both a 
greater number of specific armed effector cells and many more non-specific inflammatory cells to that 
site (Janeway et al. 2001b).  
In addition to homing and T-cell activation, adhesion molecules are involved in a variety of other 
immune processes, such as T and B-cell maturation; adhesion molecules such as VCAM-1 and VLA-4 
on bone marrow stromal cells have been shown to play a role in B-cell maturation (Jacobsen et al. 
1996), although a full understanding of the factors that regulate B-cell differentation has yet to be 
achieved.  
2.1.3 Soluble adhesion molecules 
Additional information on cell adhesion cascades and an increased understanding of their complexity 
have been obtained over the last decade thanks to the demonstration of soluble isoforms of various 
selectins, members of the immunoglobulin superfamily and a few others in the peripheral circulation in 
concentrations of several nanograms per millilitre, as measured by commercially available sandwich 
enzyme-linked immunosorbent assays, i.e. ELISA kits.  
The physiological function of these soluble molecules is unknown, but given the importance of cell 
adhesion molecules in immune responses, the possibility has been raised that the levels of soluble 
adhesion molecules might be useful monitors of disease activity in various inflammatory disorders. 
Additionally, since in vitro studies have shown that circulating selectins and members of the superfamily 
of immunoglobulins retain functional activity, it has been proposed that the molecules have 
physiological effects in vivo by competing in cell-cell adhesion or by triggering a response in cells 
carrying counter-receptors (reviewed by Gearing and Newman 1993 and Spertini 1997). These 
mechanisms are probably overlapping, especially at sites of local production, where the concentration 
might reach an adhesion-blocking level. Indeed, elevated levels of these molecules have been frequently, 
although not conclusively, demonstrated in various inflammatory disorders such as trauma, bacterial 
infections, cancer and many autoimmune diseases.  
There are several points worth bearing in mind when evaluating the clinical usefulness of soluble 
adhesion molecules, however. It is not known whether the measurable systemic levels reflect increased 
synthesis or release at the tissue level, since the affinity and the association rate constants of soluble 
adhesion molecules for ligand-bearing cells remain to be established. Significant proportion of the shed 
molecules may be unavailable, for instance, due to adhesion to cells that have counter-receptors. In some 
cases the measurable concentration may reflect decreased clearance, or both, since very little is known 
about the mechanisms of clearance or the circulating half-life of these molecules. Absolute average 
values cannot be compared between studies since different, unstandardized ELISA kits can report 
variable concentrations in the same samples due to differences in antibody specificity and in the 
standards used. Furthermore, although systemic information is scarce, there are indications that soluble 
adhesion molecule concentrations in the sera of healthy children may differ from those of normal 
healthy adults, the information provided by the ELISA kits suggesting age-related expression of cell 
adhesion molecules (Nash et al. 1996, Paronen et al. 1996, Sack et al. 1998, Ponthieux et al. 2003), 
whereas no sex-related difference has been observed in childhood (Andrys et al. 2000, Ponthieux et al. 
2003).  
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This chapter will focus on the structure and function of soluble L-selectin and ICAM-1, the soluble 
forms of which have been measured in this work. A series of other soluble adhesion molecules have 
been identified, including P and E-selectin, LFA-3, VCAM-1 and ICAM-3. 
L-selectin is shed from the surface of leukocytes following their activation (Kishimoto et al. 1989, 
Griffin et al. 1990, Jung and Dailey 1990), a major portion of the extracellular domain of the molecule 
being released from the cell surface by enzymatic cleavage (reviewed by Meager et al. 1996).The shed 
form, i.e. soluble (s)L-selectin, is detectable in serum and other body fluids circulating in at least two 
isoforms: a smaller one with a molecular weight of 62 kDa and a larger one with a molecular weight of 
75-100 kDa, which are thought to represent the same fragment although differently glycosylated and 
derived from lymphocytes and neutrophils, respectively (Schleiffenbaum et al. 1992, Gearing and 
Newman 1993). The time-course of L-selectin shedding from activated T lymphocytes is substantially 
slower than that from neutrophils, as its expression decreases several hours to several days after T-
lymphocyte activation, whereas it disappears within minutes of the exposure of neutrophils to activating 
stimuli (Spertini 1997). The physiological significance of L-selectin release from the cell surface is not 
understood. Initially, it was proposed that this was required for leukocytes to detach from the endothelial 
cell surface before entry into tissues (Kishimoto et al. 1989). Alternatively, it was proposed that rapid L-
selectin shedding modulates the leukocyte’s ability to migrate and enter sites of inflammation (Griffin et 
al. 1990). Nevertheless, the shed forms of L-selectin are bioactive and both in vitro and in vivo studies 
indicate that the increased sL-selectin levels present in certain pathological conditions may adversely 
affect leukocyte migration (Schleiffenbaum et al. 1992, Gearing and Newman 1993, Tu et al. 2002).  
Increased levels of sL-selectin have been observed especially in haematological malignancies (Stucki 
et al. 1995, Spertini et al. 1997), while smaller increases have been reported in patients with various 
inflammatory diseases, including type 1 diabetes. Reduced levels have been reported in patients with a 
high risk of developing acute lung injury in connection with the adult respiratory distress syndrome. 
This is thought to be due to sequestration of the circulating sL-selectin by binding to activated 
endothelium in the microvascular beds of pulmonary blood vessels (Donnelly et al. 1994). 
The circulating form of ICAM-1 (sICAM-1) is detectable in at least three molecular forms, the 
smallest having a molecular weight of about 240 kDa, the next 430 kDa and the largest more than 500 
kDa (Seth et al. 1991). The proportions of the isoforms seem to vary between individuals. The reason for 
the variation is not known but may be explained by complex formation between the sICAM-1 molecules 
or between these and other molecules in the plasma, or different mRNA transcripts, as described by 
Simmons et al. (1988). sICAM-1 contains most of the extracellular region of the cell-bound ICAM-1, 
suggesting that it is most likely generated by proteolytic cleavage of cell surface ICAM-1 (Spertini 
1997). Since sICAM-1 retains the ability to bind to LFA-1, it could potentially act as a carrier molecule 
that neutralizes excess ligand and prevents it from binding to cell surface ICAM-1, and accordingly it 
has been implicated as being able to regulate cell adhesion. Alternatively, sICAM-1 could be the indirect 
consequence of inflammation or tissue damage, and thus provide useful information as a marker of 
inflammatory disease. The first suggestion was that mononuclear cells were the cellular source of 
sICAM-1 (Rothlein et al. 1991), but later on it was shown to be distributed on most types of cells (von 
Andrian and Mackay 2000). The mean sICAM-1 levels detected in healthy blood donors in various 
studies range from 100 to 450 µg per litre (Spertini 1997).  
Increased circulating sICAM-1 levels have been reported in a series of inflammatory disorders, such 
as acute trauma, acute asthma, atopic dermatitis, multiple sclerosis with clinically active disease, various 
rheumatic diseases, active Crohn’s disease, vascular diseases, sepsis, episodes of graft rejection and 
cancer. Increased levels have also been observed in the cerebrospinal fluid of patients with inflammatory 
neurological diseases and in synovial fluid from patients with rheumatoid arthritis. Bacterial diseases 
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have been reported in some studies to increase serum sICAM-1 concentrations (Edgar et al. 2002), while 
other reports have remained negative in this respect (Darai et al. 2002). At least some enteroviruses, 
respiratory syncytial virus (RSV) and human rhinoviruses have been reported to use ICAM-1 as their 
receptor (Racaniello 1995, Smyth et al. 1997, reviewed by van Kempen et al. 1999). RSV (Smyth et al. 
1997) and cytomegalovirus (Furukawa et al. 1993) have been observed to increase serum levels of 
sICAM-1, although Kulander et al. (2001) were unable to detect elevated serum sICAM-1 
concentrations in 35 adult patients with evidence of viral infection, in contrast to patients with bacterial 
infections.  
 
 
2.2 Type 1 diabetes 
2.2.1 Epidemiology of the clinical disease  
The incidence of type 1 diabetes varies widely around the world, with annual rates in children younger 
than 15 years of age ranging from less than 1 per 100 000 children in China to 45 in Finland (Karvonen 
et al. 2000, Tuomilehto et al. 1999), i.e. the global variation in its incidence is more than 400-fold, and 
up to tenfold even within Europe (EURODIAB ACE Study Group 2000). Most populations in Asia and 
South America have a very low incidence, while the highest rates are found in northern and north-
western Europe, North America and New Zealand (Karvonen et al. 2000, EURODIAB ACE Study 
Group 2000). In most populations the incidence is highest among children aged 10-14 years (Karvonen 
et al. 2000).  
The incidence of childhood diabetes has increased steadily in most populations over the past 30-50 
years, particularly in countries with a low initial incidence (Onkamo et al. 1999, Gale 2002). The 
EURODIAB collaborative study, a registry consortium involving 44 centres in most European countries 
and Israel, indicates an annual rate of increase of 3-4%, but in some central and eastern European 
countries the increase is far more rapid.  
Although an increase has been seen in all age groups in Europe (EURODIAB ACE Study Group 
2000) it has been extremely rapid over the past 10-20 years in the under fives (Tuomilehto et al. 1999, 
Gardner et al. 1997, EURODIAB ACE Study Group 2000). Thus, rather than a general increase in all 
age categories, a shift towards younger age at diagnosis has been suggested (Pundziute-Lyckå et al. 
2002, Weets et al. 2002). The overall sex ratio in children diagnosed under the age of 15 years is roughly 
equal (Karvonen et al. 2000, Pundziute-Lyckå et al. 2002), while populations with a very high incidence 
of type 1 diabetes show a male excess, especially among those diagnosed after puberty (Tuomilehto et 
al. 1992, reviewed by Gale and Gillespie 2001).  
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2.2.2 Aetiology and pathogenesis 
2.2.2.1 Genetic susceptibility  
Family and twin studies have shown that type 1 diabetes has a genetic basis, but the inheritance of the 
disease does not follow a simple mendelian single-locus pattern. The major genetic determinants reside 
in the human leukocyte antigen (HLA) gene region within the MHC on the short arm of chromosome 6, 
as these gene loci are thought to contribute about 45% of its heritability. The function of these genes in 
the mounting of any immune response is well known, i.e. presentation of antigenic peptides to the T 
lymphocytes. It is hypothesized that susceptible HLA-DR and DQ molecules bind diabetogenic antigens 
with low affinity and allow self-reactive T cells from the thymus to escape into the periphery, while 
protective HLA molecules bind with high affinity, resulting in negative selection of autoreactive T cells 
in the thymus. This implies that rather than predisposing the subject to autoimmune disease, the HLA 
genes fail to provide efficient protection (reviewed by Field 2002).  
Type 1 diabetes is most closely associated with the DR, DQA1 and DQB1 alleles of the HLA class II 
loci (Table 2). Various DR4 allelic variants modify DQB1-associated susceptibility to type 1 diabetes, 
whereas protection is conveyed by DQB1*0602, linked to DR2. In Caucasians DQB1*0302 and 
DQB1*02 and their linked DR specificities DR3 and DR4 provide disease susceptibility, particularly in 
the heterozygous combination, as the DR3/4 phenotype is present in 30-50% of patients with type 1 
diabetes and only 1-6% of the background population (reviewed by Wassmuth and Lernmark 1989 and 
Deschamps and Khalil 1993). The heterozygous DQB1*0201/0302 genotype is found in 25% of patients 
and in only 3% of healthy controls. DQB1*0302 alone, without protective alleles such as DQB1*0602 
and 0603, is associated with moderate risk (Ilonen et al. 1996), and such a genotype is found in 70% of 
patients with type 1 diabetes, while the corresponding frequency among healthy controls is 20-30% 
(Reijonen et al. 1997). Pugliese et al. (1995) reported that DQB1*0602 is present in 0.5% of patients 
with type 1 diabetes and in 20-25% of the general population. The protective effect of DQB1*0602 is 
dominant over the susceptibility conferred by the high-risk DQB1 alleles (Baisch et al. 1990, Pugliese et 
al. 1995). Age at onset may be influenced by DQB1*0602, as this protective allele was absent in patients 
diagnosed before the age of 10 years, but increased in frequency with increasing age at onset (Kockum 
et al. 1996). 
Another genetic determinant of susceptibility to type 1 diabetes has been confirmed as residing on 
chromosome 11p15, which contains the insulin gene region, and this polymorphism has been said to 
explain about 5-10% of the heritability of type 1 diabetes. The mechanism by which this gene region is 
involved in the disease process has yet to be ascertained, but it has been shown that the protective 
genotype is characterized by increased expression of insulin in the developing thymus, which could 
promote immune tolerance of insulin and thereby reduce the predisposition to autoimmunity (Pugliese et 
al. 1997, Vafiadis et al. 1997).  
A locus on chromosome 2 harbouring the gene encoding the cytotoxic T lymphocyte antigen 4 
(CTLA-4) has been shown to be associated with susceptibility to autoimmune diseases, including 
autoimmune thyroiditis and type 1 diabetes (Ueda et al. 2003) 
In addition to HLA, the insulin gene region and the CTLA-4 region, about 20 other chromosomal 
regions have been identified in genome-wide screening as loci potentially associated with a genetic 
predisposition to type 1 diabetes. It is conceivable that, in addition to genes regulating the immune 
system, genes related to beta-cell development might also be involved (Field 2002).  
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Table 2. Some combinations of DQA1 and DQB1 genes associated with type 1 diabetes susceptibility or 
protection in Black, Caucasian  and Japanese subjects (modified from Thorsby and Rønningen 1993), 
DQA1 allele DQB1 allele Position† DQ serotype DR serotype‡ Ethnic group 
 
Susceptibility     
*0301 *0302 cis DQ8 DR4 all 
*0501 *0201 cis DQ2 DR3 all 
*0301 *0201 cis/trans   all 
*0501 *0302 trans   all 
*0301 *0402 trans   all 
Protection      
*0102 *0602 cis DQ6 DR2,DR11 all 
*0103 *0603 cis DQ6 DR6 Black and Caucasian subjects 
*0501 *0301 cis DQ7 DR5 all 
† cis  (on the same haplotype) or trans (on a different haplotype) position of the DQA1 and DQB1 genes 
‡ commonly associating DR serotype 
2.2.2.2 Role of environmental factors 
Despite extensive research, no environmental agent(s) responsible for triggering/precipitating the 
pathogenetic process involved in type 1 diabetes have definitively been identified. An apparent seasonal 
variation in the clinical presentation of type 1 diabetes, with a peak in the autumn, a characteristic often 
linked to viral infections, was reported for the first time almost 70 years ago (Adams 1926), and viruses 
have been implicated in the pathogenesis of type 1 diabetes. Other major influences proposed are dietary 
factors, particularly early infant diet, and toxins. As all the potential major risk factors interact in the 
gut-associated lymphoid tissue, the role of the gut immune system in the development of type 1 diabetes 
has received a lot of attention recently (Harrison and Honeyman 1999, reviewed by Vaarala 1999). The 
young age at diagnosis and the long prodrome, on the other hand, both suggest that for the majority of 
patients the disease process may have its origins in early life (Leslie and Elliott 1994).  
The association between congenital rubella virus infections and the development of human diabetes 
is well established, although most recent data indicate that the form of diabetes associated with this lacks 
signs of beta-cell autoimmunity (Viskari et al. 2003). The possible connection between type 1 diabetes 
and many other viruses, such as mumps, chickenbox, measles, cytomegalovirus, Epstein-Barr virus and 
rotavirus, is a controversial issue (reviewed by Hyöty and Taylor 2002). Currently the main candidate 
for involvement in the pathogenesis of human type 1 diabetes is the group of enteroviruses, which 
comprise more than 60 serotypes including the polioviruses, coxsackie A and B viruses and echoviruses. 
Infection with various serotypes is common, starting as early as during the first months of life, and the 
virus frequently causes a viraemia (Hyöty and Taylor 2002). Age is one of the principal host-related 
factors affecting the incidence and outcome of enterovirus infections, which are more frequently seen in 
young children. Coxsackie B virus infections in particular have been reported to be more severe in 
neonates than in older children and adults (Mackay-Scollay et al. 1973, Melnick 1996). The timing and 
the infectiousness of the virus strain may also be critical for diabetogenicity. 
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There are several lines of evidence to suggest that an enterovirus infection may be involved in 
inducing the autoimmune process leading to human type 1 diabetes. A recent case report of an infant 
affected by neonatal autoimmune diabetes associated with a maternal echovirus 6 infection acquired 
during pregnancy suggests that enteroviral infections may induce beta-cell autoimmunity even in utero 
(Otonkoski et al. 2000). In the prospective Childhood Diabetes in Finland (DiMe) study, enterovirus 
infections, diagnosed by antibody assays and by the presence of viral RNA in serum, were observed to 
be more frequent in the time period preceding the appearance of autoantibodies in the initially non-
diabetic siblings who became diabetic than in non-diabetic (or antibody-negative) control siblings 
(Hyöty et al. 1995). A seasonal pattern in the appearance of the first autoantibodies similar to that of 
enterovirus infections, with peaks in the autumn and winter months, has been reported in Finland 
(Kimpimäki et al. 2001b). These findings were confirmed in the prospective Type 1 Diabetes Prediction 
and Prevention (DIPP) study cohort followed from birth, in that enterovirus infections were almost twice 
as frequent in the subjects who became autoantibody-positive than in sex and HLA-matched control 
children. Infections were also clustered during the 6 months period preceding the first appearance of 
autoantibodies (Lönnrot et al. 2000). The German BABYDIAB study, however, did not find any 
association between serologically verified enterovirus infections and the development of beta-cell 
autoimmunity in children genetically prone to type 1 diabetes (Füchtenbusch et al. 2001).  
Viruses can act by at least two possible mechanisms, either via a direct cytolytic effect or by 
triggering an autoimmune process leading gradually to beta-cell destruction. The suggested virus-
induced autoimmune process could include modification of the surface antigens to immunogenic forms, 
e.g. by up-regulation of cytokines, MHC class I and/or class II molecules (reviewed by Jun and Yoon 
2003) and, as recently suggested, adhesion molecules (Zanone et al. 2003) on the target tissue of the 
host. Structural similarities between antigenic epitopes on the virus and molecules in the host tissue 
could lead to the generation of antigen-specific effector T cells and/or antibodies that recognize target 
cells (molecular mimicry) (Jun and Yoon 2003). An alternative mechanism for initiating autoimmunity 
is thought to occur through bystander T-cell activation; i.e a local infection induced by an enterovirus 
may lead to inflammation, tissue damage and the release of islet antigens, resulting in the re-stimulation 
of resting autoreactive T cells (Horwitz et al. 1998). 
Diabetic children have been reported to experience infections during the year preceding diabetes 
onset more often than control subjects (Blom et al. 1991, Verge et al. 1994), implying that infections 
may precipitate the on-going beta-cell destruction and reveal the already existing insulin deficiency by 
increasing the insulin need. Attendance at pre-school day-care, which increases the frequency of most 
common childhood infections, has been reported to provide protection against type 1 diabetes 
(EURODIAB Substudy 2 Study Group 2000, Kaila and Taback 2001), and there is some evidence from 
animal experiments and indirect epidemiological associations in humans to suggest that a lack of 
immune stimulation due to insufficient exposure to infections early in life might increase the risk of 
contracting type 1 diabetes (Gale 2002). An inverse association between the number of infections during 
the first year of life and the risk of diabetes has been reported in Southampton, UK (Gibbon et al. 1997) 
and in a group of children in Lithuania who developed diabetes after the age of 4 years (Pundziūte-
Lyckå et al. 2000). No association between early infections and the risk of type 1 diabetes was observed 
in a Swedish study (Blom et al. 1991). 
The immune system is functionally immature during fetal life and in early infancy, when tolerance to 
various antigens is induced. Additionally, the gut is more permeable to proteins during the first months 
of infancy (Jakobsson et al. 1986, Kuitunen et al. 1994). Early infancy is a time of rapid growth and 
development, in which certain periods may be critical for later health. Early introduction of cow’s milk 
into the infant diet and/or short duration of breast-feeding have been implicated in an increased risk of 
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type 1 diabetes. The risk of diabetes was shown to decrease in BB (biobreeding) rats and NOD mice 
when they were fed with synthetic amino acid and casein hydrolysate diets instead of standard intact 
casein-containing diets (reviewed by Åkerblom and Knip 1998). A diabetogenic effect of cow’s milk 
proteins was seen during a relatively narrow weaning period in BB rats (Daneman et al. 1987). The 
protective effect of breast milk has been attributed either to an antiviral property of human milk or 
alternatively to the early introduction of foreign antigens such as cow’s milk proteins in association with 
the early cessation of breast-feeding (Kostraba et al 1993).  
Early introduction of supplementary cow’s milk-based formula was shown to entail an increased risk 
of type 1 diabetes (Virtanen et al. 1993, Verge et al. 1994), although two meta-analyses of multiple 
studies in which diabetes prevalence was associated retrospectively with infant feeding revealed only a 
marginal increase (reviewed by Davis 2001). The risk attached to early cow’s milk exposure or short 
duration of breast-feeding in relation to the type 1 diabetes has been reported to be dependent on the age 
at diagnosis, in that the younger the patient is, the higher is the risk (Dahlquist et al. 1991). Moreover, 
genetic susceptibility appears to increase the risk, so that Kostraba et al. (1993 ) reported relative risks of 
11.3 and 13.1 for children with HLA susceptibility genes who had early exposure to cow’s milk or 
shorter periods of breast-feeding.  
Kimpimäki et al. (2001a) showed in a recent prospective study of Finnish genetically susceptible 
young children that short-term breast-feeding, i.e. less than two months, and the early introduction of 
cow’s milk-based formula predisposes these subjects to progressive signs of beta-cell autoimmunity, i.e. 
the development of IA-2A or of all four autoantibodies. Prospective studies of high-risk infants in 
Germany, the United States and Australia have failed to confirm any association between the duration of 
breast-feeding or early introduction of cow’s milk formula and the development of islet cell 
autoimmunity (Norris et al. 1996, Couper et al. 1999, Hummel et al. 2000). A large-scale intervention 
study, Trial to Reduce IDDM in the Genetically at Risk (TRIGR), is now running in HLA-susceptible 
offspring of families with at least one affected member to explore whether the elimination of cow’s milk 
proteins over the first 6-8 months of life results in a reduced risk of beta-cell autoimmunity and 
progression to clinical diabetes. 
Viral infections may interact with exposure to cow’s milk proteins, as among genetically susceptible 
infants exposed to cow’s milk before the age of three months, those who had a T-cell proliferation 
response to enterovirus antigen at the age of three months had higher concentrations of antibodies to 
bovine insulin at the ages of six and nine months than infants who had no T-cell response to enterovirus 
antigen (Vaarala et al. 2002). 
Plant proteins, i.e. wheat protein gluten and soy, have been shown in some animal experiments to be 
diabetogenic (Åkerblom and Knip 1998). Dietary supplementation with foods containing gluten before 
the age of three months has been reported to be associated with a four-fold risk of the appearance of 
diabetes-associated autoantibodies as compared with children who received only breast milk until the 
age of three months among the offspring of affected parent(s) who had HLA-conferred susceptibility to 
type 1 diabetes (Ziegler et al. 2003). Norris et al. (2003) found a four to five-fold risk of developing IA-
2 antibodies if the child was exposed to cereals before the age of three months or at the age of seven 
months or later, the respective HLA-adjusted hazard ratios in children with the highest risk genotypes 
being 5 and 12. Prenatal and early postnatal vitamin D supplementation is associated with a decreased 
risk of type 1 diabetes (EURODIAB Substudy 2 Study Group 1999, Hyppönen et al. 2001).  
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2.2.2.3 Autoimmunity 
2.2.2.3.1 Humoral autoimmunity  
The phase of active beta-cell autoimmunity is characterized by circulating autoantibodies that react with 
antigens in the pancreatic islet cells. Although the pathogenesis of type 1 diabetes is obviously T-cell-
mediated, epidemiological studies have defined autoimmunity as the presence of autoantibodies, since in 
contrast to the cellular markers, their measurement is reliable and standardized across laboratories. 
Several islet cell autoantigens and related antibodies have been identified, but only a few of them are 
clinically relevant with regard to diabetes prediction. Earlier studies have described the epidemiology of 
beta-cell autoimmunity by measuring islet cell antibodies (ICA) with the classical immunofluorescence 
test using pancreatic tissue. This test has been difficult to standardize and has been replaced in most 
laboratories by a combination of assays for antibodies against biochemically characterized autoantigens 
such as insulin, glutamic acid decarboxylase (GAD) or ICA512 (IA-2). These tests are quite sensitive 
and predictive in relatives of patients with type 1 diabetes, and also in the general population. Prediction 
on the individual level, however, has proven to be a complicated issue, since not all subjects with 
autoantibodies seem to progress to clinical type 1 diabetes. The prevalence of beta-cell autoimmunity is 
definitely higher than that of clinical type 1 diabetes (Williams et al. 2002).  
ICA were first detected in patients with polyendocrinopathy including type 1 diabetes, suggesting 
that humoral autoimmunity is involved in the development of the latter (Bottazzo et al.1974). The 
semiquantitative assay uses frozen sections of human pancreas, and as a consequence it is labour-
intensive and difficult to standardize and reproduce. Quantitative radioimmunoassays with high 
specificity and sensitivity for type 1 diabetes are now available in the case of three major islet 
autoantigens: insulin, glutamic acid decarboxylase (in particular GAD65) and ICA512/IA-2. GAD65 
and IA-2 are the principal autoantigens recognized by antibodies in the ICA test, but ICA also include 
autoantigens reacting with other, so far unidentified antigens. 70-90% of patients test positive for ICA at 
diagnosis. The frequency of ICA varies from about 5 to 12% among first-degree relatives of patients 
with type 1 diabetes, depending on the cut-off point chosen for antibody positivity, and from 0.2 to 4% 
in the general population.  
The frequency of antibodies to GAD65 (GADA) varies from 60 to 85% among patients with newly 
diagnosed type 1 diabetes, from 3 to 6% among siblings of children with type 1 diabetes and from 0.5 to 
3% among children in the general population. The prevalence of antibodies to IA-2 (IA-2A) varies from 
50 to 85% in patients with newly diagnosed type 1 diabetes, being 1.5-5% among siblings of children 
with type 1 diabetes and 0.2-2% in children from the general population. Correspondingly, antibodies to 
insulin (IAA), the only beta-cell-specific autoantigen so far identified, have been observed with a 
frequency of 30% among adult patients at diagnosis and up to 80% among children diagnosed before the 
age of 5 years. An inverse association is observed between both the frequency and the titre of IAA and 
age (Kulmala et al. 1998, Komulainen et al. 1999, Ziegler et al. 1999). 1.5-7% of siblings of children 
with type 1 diabetes test positive for IAA and 1-3% of children representing the general population.  
2.2.2.3.2 Cellular autoimmunity  
There are several lines of evidence to suggest that the cellular arm of the immune system is involved in 
the destruction of pancreatic beta cells. T-cell-dominated infiltrates are seen in the pancreatic islets of 
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most patients at the time of diagnosis of type 1 diabetes (Gepts 1965, Hänninen et al. 1992, Imagawa et 
al. 2001), and they have also been shown to be present in patients with residual beta-cell function, 
implying continuous insulitis before total destruction (Shimada et al 1999). ”Adoptive” type 1 diabetes 
has been shown to develop following transplantation with bone marrow undepleted for T cells from a 
diabetic donor to a related non-diabetic immunocompromised recipient (Lampeter et al. 1993). 
Immunosuppressive drugs specifically directed against T cells have been reported to delay the disease 
process (Bougneres et al. 1988).  
Several groups have demonstrated the presence of activated T cells that respond to human beta cells 
(Peakman et al. 1994, Roep et al. 1995) or beta cell-associated proteins (Kallan et al. 1995) in the 
peripheral circulation of patients with newly diagnosed type 1 diabetes or prediabetic subjects. On the 
other hand, a high frequency of T-cell responses to diabetes-associated autoantigens has also been 
described in healthy controls (Schloot et al. 1997, Rharbaoui et al. 1999).  
Unlike the situation with autoantibodies, assays of human T-cell function rely on the ability of the in 
vitro systems to mimic in vivo situations at the site of inflammation, e.g. the pancreatic islets or draining 
lymph node, where activated T cells would be expected to be highly concentrated while the 
corresponding levels in the peripheral circulation are much lower. The reported discrepancies are partly 
attributable to the obvious limitations in the currently available T-cell assay technology and the quality 
of the antigen preparations, which has proved to be critical with regard to accurate measurements of 
circulating autoreactive T cells (reviewed by Roep 2003).  
The NOD mouse is a spontaneous animal model for autoimmune diabetes, as all mice of this strain 
develop humoral autoimmunity to islet cell antigens soon after birth. The infiltration of islets with 
mononuclear cells starts at about 3-5 weeks of age, beginning from the periphery and progressing to the 
islet core. Peri-insulitis usually has little beta-cell destruction associated with it and does not cause 
insulin deficiency until a precipitating event, or a genetic programme, induces islet invasion by 
macrophage/dendritic cells, CD4 and CD8-positive T cells. The majority of female mice develop overt 
insulin-dependent diabetes by 13-30 weeks of life (Leiter et al. 1987, reviewed by Lampeter et al. 1989). 
Peri-insulitis in the NOD mouse is characterized by high levels of type 2 helper T cell (Th2) cytokines, 
such as IL-4 and IL-10, and low levels of type 1 helper T cell (Th1) cytokines such as IFN-γ (Healey et 
al. 1995, Kolb 1997). Destructive intrainsulitis is characterized by a dominance of Th1 cytokines such as 
IFN-γ, IL-2 and IL-12 (Rabinovitch 1994, Fujihira et al. 2000).  
Although not demonstrated sequentially, a similar course of events may occur in humans (Shimada 
et al. 1999). A bias towards Th1-type immune reactivity has been observed in immune cells grown from 
the blood of patients with type 1 diabetes (Kallmann et al. 1999) and a Th1-dominated cytokine profile 
has also been verified in subjects at risk for the disease (Hussain et al. 1998, Karlsson et al. 2000).  
2.2.3 Expression and role of adhesion molecules during the pathogenesis of type 1 
diabetes 
2.2.3.1 In human type 1 diabetes 
Some of the published work on human type 1 diabetes has compared the expression of certain cell 
adhesion molecules in recent-onset diabetic pancreata with that in the pancreas of subjects without 
diabetes. Thus increased ICAM-1 expression was detected in vascular endothelial cells by 
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immunostaining but not in vessels from uninflamed pancreases (Hänninen et al. 1992), while Itoh et al. 
(1993) found strong endothelial ICAM-1 expression in two out of nine cases and Somoza et al. (1994) in 
one recent diabetic pancreas. In addition, VCAM-1 expression was found in morphologically identified 
dendritic cells scattered around the islets of the diabetic pancreas (Hänninen et al. 1992, Somoza et al. 
1994), while the expression of LFA-1 and LFA-3 did not differ from that in control pancreata (Somoza 
et al. 1994). Although ICAM expression in beta cells has been reported to be an effect induced by 
cytokines in vitro and in vivo (Vives et al. 1991), no ICAM-1 expression in human endocrine cells was 
found within the islets (Hänninen et al. 1992, Itoh et al. 1993, reviewed by Yang et al. 1996).  
Aberrations in the gut immune system have been implicated in the pathogenesis of type 1 diabetes 
(Vaarala 1999). Studies performed on NOD mice and patients with type 1 diabetes show that the islet-
infiltrating autoreactive cells express gut-associated homing receptor α4β7 integrin, suggesting the 
recirculation of lymphocytes between the gut and the pancreas (Yang et al. 1996, Hänninen et al. 1996 
and 1998, Paronen et al. 1997). Inflammation and immune activation, such as enhanced expression of 
HLA-DR and ICAM-1 on the gut epithelium and α4β7 integrin on the T cells in the lamina propria, was 
demonstrated by immunohistochemistry of the macroscopically normal intestines of patients with type 1 
diabetes without signs of coeliac disease compared with control subjects. The findings were not 
restricted to HLA-DQ2 risk alleles, which are associated with coeliac disease, suggesting that 
subclinical inflammation of the gut may be an underlying entity in type 1 diabetes (Savilahti et al. 1999, 
Westerholm-Ormio et al. 2003).  
The mean proportions of stimulated monocytes expressing detectable amounts of the adhesion 
molecules LFA-1 and ICAM-1 have been reported to be lower in 13 patients 2-3 weeks after the 
diagnosis of type 1 diabetes than in normal controls, a finding thought to indicate trapping of cells 
expressing these adhesion molecules in the inflamed organ (Martin et al. 1991). This was also shown 
with two analyses of peripheral blood mononuclear cells in patients with Grave’s disease, who similarly 
had a reduced number of cells expressing adhesion molecules (Guerin et al. 1989, Kabel et al. 1990). 
Lampeter et al. (1992) reported elevated levels of sICAM-1 (>2 SD of the normal mean observed in 100 
healthy blood donors) in four out of 14 patients with newly diagnosed type 1 diabetes, and of sL-selectin 
in nine out of 14 such patients. Among the six ICA-positive first-degree relatives, increased levels of 
soluble ICAM-1 were observed in half of the cases and increased sL-selectin in all of them, but ICA-
negative relatives with an increased genetic risk of type 1 diabetes (HLA-DR3 and/or DR4) also had 
increased sICAM-1 and sL-selectin concentrations (Lampeter et al. 1992).  
Based on these findings, Lampeter et al. (1992) suggested that the reduced expression of ICAM-1 on 
the surfaces of monocytes (Martin et al. 1991) and the elevated serum concentration could result from 
enhanced shedding of ICAM-1, while the increased levels of soluble ICAM-1 and L-selectin could 
reflect an on-going immune process during which soluble adhesion molecules are released. In line with 
this finding, Myśliwiec et al. (1999) also reported the highest sICAM-1 levels in 26 prediabetic first-
degree relatives, i.e. subjects with ICA 20 JDFU or more, of whom 20 had multiple autoantibodies, 
either GADA, IA-2 and/or IAA, compared with the levels observed in age-matched healthy controls and 
patients with clinical type 1 diabetes. Krętowski et al. (2000a) reported increased levels of sL-selectin in 
patients with newly diagnosed type 1 diabetes and in patients with untreated Graves’ disease, and also in 
first-degree relatives both with and without autoantibodies associated with type 1 diabetes, compared 
with the levels observed in healthy controls and patients with type 2 diabetes. They also observed that 
the proportion of memory T lymphocytes expressing L-selectin had decreased in patients with newly 
diagnosed type 1 diabetes and in relatives with two or more autoantibodies by comparison with healthy 
controls, and attributed this to alterations in the balance of cytokines produced by helper T cells 
(Th1/Th2) (Krętowski et al. 2000a). Human memory CD4-positive T cells expressing L-selectin have 
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been shown to produce mainly IL-4 and IL-5, whereas L-selectin-negative CD4-positive T cells 
produced mainly IFN-γ. This profile of cytokine expression coincides with that which distinguishes the 
Th1 and Th2 subsets (Kanegane et al. 1996). An inverse correlation was seen between the ratio of L-
selectin-positive and negative helper T lymphocytes and circulating sL-selectin in subjects with type 1 
diabetes and autoantibody-positive relatives. High sL-selectin levels correlated with the presence of 
high-risk diabetes-associated HLA alleles both in family members and in controls. The group suggested 
that sL-selectin could serve as a late marker of the autoimmune destruction of beta cells (Krętowski et 
al. 2000a). Increased concentrations of sL-selectin have been observed in 35 children and adolescents 
with recent-onset type 1 diabetes compared with the levels in patients who had received insulin 
treatment for 2-12 months, in patients with a disease duration of more than one year and in non-diabetic 
controls (Kordonouri and Bührer 2000).  
Increased levels of sICAM-1, sVCAM-1 and/or sE-selectin have been extensively reported in adult 
patients with type 1 and 2 diabetes, and it has been implied that these may be involved in the 
pathogenesis of diabetic vascular disease, since at least ICAM-1 expression in endothelial cells has been 
observed to be increased under high-glucose conditions (Taki et al. 1996). 
2.2.3.2 In vitro   
Roep et al. (1994) reported that a monomeric soluble recombinant form of ICAM-1 inhibited specific 
anti-beta-cell T-cell responses in concentrations similar to those found in first-degree relatives at risk for 
type 1 diabetes (Lampeter et al. 1992), implying that a naturally circulating elevated concentration of 
sICAM-1 may down-regulate T-cell inflammation in subjects at risk of developing type 1 diabetes rather 
than reflecting subclinical insulitis. In such a scenario, increased circulating concentrations of sICAM-1 
would represent a defensive mechanism against beta-cell destruction. It was suggested that the 
mechanism by which the recombinant form of ICAM-1 blocked the antigen-specific T-cell proliferation 
may depend on the interaction between T cells and antigen-presenting cells (Roep et al. 1994). 
 
2.2.3.3 In murine models  
The expression of cell adhesion molecules on the surface of lymphocytes and endothelial cells in the 
NOD mouse pancreas during the diabetic process has been investigated using semiquantitative 
immunohistochemistry. The expression of some adhesion molecules is up-regulated in parallel with the 
development of insulitis, while that of others remains unchanged. A low constitutive expression of 
MAdCAM-1 is found on the endothelial cells of many vessels in the exocrine pancreas of both NOD 
and control mice during the first three weeks after birth, but not on the endothelium within the islets. 
Vessels with the morphology of HEV and endothelial expression of MAdCAM-1 and PNAd were 
reported to develop within and adjacent to pancreatic islets at the time when T cells enter these islets 
(Hänninen et al. 1993). MAdCAM-1 seems to be the predominant addressin expressed on endothelial 
cells in and adjacent to the islets at the early stages of insulitis, while the expression of PNAd increases 
as insulitis progresses. Most infiltrating lymphocytes express α4β7 integrin at all stages of insulitis and 
the expression of α4β7 on lymphocytes correlates with high expression of MAdCAM-1 by endothelial 
cells, suggesting a predominant role for mucosal lymphocyte homing in the development of insulitis. A 
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minority of the peri-islet and intra-islet lymphocytes present during the early stages of insulitis 
expressed L-selectin, but this expression intensified on groups of lymphocytes within the inflammatory 
plaque at more advanced stages of insulitis (Hänninen et al. 1993, reviewed by Yang et al. 1996).  
Faveeuw et al. (1994) have demonstrated ICAM-1 expression on endothelial and dendritic cells in 
infiltrated islets of 14 to 17-week-old NOD mice, while it was absent in healthy areas, suggesting that 
ICAM-1 is involved in the migration of murine lymphocytes into the islets of Langerhans. The same 
group also reported the presence of VCAM-1-positive dendritic cells in inflamed islets of NOD mice. 
Martin et al. (1996) reported that cryostat sections of NOD mouse pancreas islets did not show any 
expression of ICAM-1, LFA-1, L-selectin or VCAM-1 prior to infiltration by mononuclear cells. ICAM-
1 and LFA-1 were first demonstrable with strong peri-insular infiltrates, while L-selectin and VCAM-1 
were only seen in islets with mild or strong intra-islet infiltration. The staining pattern for the four cell 
adhesion molecules was consistent with both T-cell and macrophage infiltration and the distribution of 
the two cell types in the infiltrate largely overlapped. Adhesion molecule expression was shown to be 
similar during Th1 and Th2-cell infiltration, suggesting similar adhesion molecule requirements for the 
two Th subsets (Martin et al. 1996). More recently, the same author suggested on the basis of findings in 
NOD mice with a disrupted ICAM-1 gene that ICAM-1 has a non-replaceable role in T-cell activation 
prior to islet inflammation, since in its absence the NOD mice fail to mount any strong autoaggressive 
Th1 response (Martin et al. 2001). In line with this, Balasa et al. (2001) have suggested a role for ICAM-
1 in the generation and/or expansion of islet-specific T cells. Interactions of LFA-1 with ICAM-1 during 
priming have been shown to generate effector T cells capable of destroying murine beta cells (Camacho 
et al. 2001). 
Administration of 5 µg of recombinant ICAM-1 proteins three times a week for 4.5 months from the 
age of 35 days onwards has been shown to inhibit insulitis and the onset of autoimmune diabetes in 
NOD mice (Martin et al. 1998). Similarly, monoclonal antibodies (Mab) directed against ICAM-1 and 
LFA-1 have been shown to inhibit the development of autoimmune diabetes in mice of this strain (Yagi 
et al. 1995, Yang et al. 1996). Respectively, treatment with Mab against L-selectin and VLA-4 (Yang et 
al. 1993) and against β7 integrin (Yang et al. 1997) and MAdCAM-1 (Hänninen et al. 1998) have been 
reported to provide protection against the spontaneous occurrence of autoimmune diabetes in NOD 
mice.  
2.2.4 Natural course of type 1 diabetes  
The natural course of type 1 diabetes includes four fairly distinct stages that can be detected in the 
majority of patients: 1) preclinical beta-cell autoimmunity with progressive impairment in insulin 
secretion capacity, 2) manifestation of clinical diabetes, 3) transient remission, and 4) established 
diabetes. 
 
2.2.4.1 Autoantibody appearance and persistence.  
Beta-cell autoimmunity can appear by the age of 6-9 months (Martikainen et al. 1996, Roll et al. 1996, 
Ziegler et al. 1999), although rarely during the first months of life (Kimpimäki et al. 2002) or as early as 
in utero (Otonkoski et al. 2000). In the DIPP birth cohort study the prevalence of children with 
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autoantibodies increased steadily with age during the first 7 years (Kupila A, personal communication). 
There is no predetermined order of emergence of various autoantibodies during the preclinical stage, 
although IAA seem to be the first or among the first autoantibodies to appear in young subjects (Ziegler 
et al. 1999, Colman et al. 2000, Kupila et al. 2002), while IA-2A are commonly among the last to appear 
(Roll et al. 1996, Kupila et al. 2002), indicating rapid progression to clinical disease.  
Subclinical beta-cell autoimmunity is present in many more individuals than the number of cases 
with type 1 diabetes that can be expected. Diabetes-associated autoantibodies can occur transiently, and 
the reported rate of transient positivity for a single autoantibody has varied between 2 and 14% within a 
follow-up period of 2-3 years in prospective birth cohort studies (Colman et al. 2000, Yu et al. 2000, 
Kupila et al. 2002). The disappearance of autoantibodies is mainly restricted to positivity for one low-
titre autoantibody, and is rarely seen among the subjects carrying high-risk (DR3/4, DQ2/8) genotypes 
(Yu et al. 2000, Savola et al. 2001). Any of the four antibodies ICA, IAA, GADA and IA-2A may 
disappear, but IAA have been observed to do so more often than ICA in unaffected schoolchildren 
(Lévy-Marchal et al. 1995), and they have also displayed a transient characteristic in young genetically 
susceptible children (Colman et al. 2000, Kimpimäki et al. 2002). Reports concerning the persistence of 
IA-2A have been conflicting. Common inverse seroconversions have been reported by Kulmala et al. 
(2000a) in unaffected schoolchildren and by Colman et al. (2000), while IA-2A proved highly persistent 
in the DIPP cohort (Kimpimäki et al. 2002). The reason for antibody fluctuations remains to be defined, 
although viral infections having no correlation to future diabetes have been suggested (Hyöty et al. 
1995). Although transient expression of autoantibodies is commonly regarded as a benign sign of self-
limited anti-islet autoimmunity, and mostly does not indicate an increased risk of type 1 diabetes, loss of 
antibody positivity does not invariably indicate the cessation of the process of pancreatic beta-cell 
destruction (Christie et al. 1997). 
 
2.2.4.2 From the onset of autoimmunity to clinical diagnosis  
The duration of preclinical beta-cell autoimmunity is highly variable and can precede the diagnosis by a 
matter of months or years. Those subjects in whom the disease process is slow may present with type 1 
diabetes as adults, so that markers of beta-cell autoimmunity can be detected in 5-30% of adult patients 
classified as having type 2 diabetes on the basis of their clinical features. The concept “latent 
autoimmune diabetes of adults” (LADA) has been coined for this slowly progressing form of 
autoimmune diabetes, which has been estimated to account for about a half of all patients affected by 
type 1 diabetes (reviewed by Atkinson and Eisenbarth 2001).  
In some subjects the process is so slow that they appear to be non-progressors or they may never 
progress to the clinical disease. No specific characteristics that could completely discriminate between 
progressors and non-progressors (or slow-progressors) have been identified so far, which supports the 
heterogeneous nature of beta-cell destruction (Knip et al. 1994, Kulmala et al. 1998, Greenbaum et al. 
1999), which is thought to be even more variable in young children (Ziegler et al. 1999). In most 
subjects with persistent autoantibodies there is progressive impairment in the acute insulin response to 
intravenous glucose, followed by a deterioration in oral glucose tolerance and fasting hyperglycaemia. 
The classical symptoms of hyperglycaemia, such as excessive drinking, increasing urinary volumes, 
weight loss and ketosis, occur late in the natural history of the disease.  
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The natural history of both preclinical and clinical type 1 diabetes may vary with age. Presentation at 
a very young age has been reported to associate with a severe metabolic decompensation and a poorly 
preserved residual beta-cell function at diagnosis (Komulainen et al. 1999). Positivity for multiple 
autoantibodies also indicates more aggressive beta-cell destruction and accelerated beta-cell failure, so 
that patients with multiple autoantibodies at diagnosis have been shown to have an increased 
requirement for exogenous insulin over the second year of clinical disease (Komulainen et al. 1999, 
Sabbah et al. 1999) and low/non-existent fasting C-peptide levels within 5 years, whereas C-peptide 
levels remained unchanged during a 12-year follow-up in initially autoantibody-negative subjects (Borg 
et al. 2002).  
Shortly after clinical presentation, most patients undergo a transient fall in their insulin requirement 
due to improved beta-cell function, reflected by an increase in circulating C-peptide concentrations and 
increasing insulin sensitivity. This phase is often referred as a “honeymoon” or remission. Mild 
metabolic derangements, male sex, older age (Knip et al. 1982, Örtqvist et al. 1997) and an absence of 
ICA (Wallensteen et al. 1988, Örtqvist et al. 1997) have been shown to be associated with a more 
pronounced and longer partial remission. Destruction of the beta cells becomes complete within a few 
years of diagnosis in most children, especially in those with the HLA-DR3/4 combination (Knip et al. 
1986). On the other hand, it has been proposed that the destructive process may be slower in patients 
who are older at diagnosis and may sometimes not result in total beta-cell destruction (Madsbad et al. 
1978, Foulis et al. 1986, Shimada et al. 1999), since 15% have been reported to have some beta-cell 
function preserved more than 15 years after diagnosis (Madsbad et al.1978).  
2.2.5 Prediction of type 1 diabetes  
Although the pathogenetic process by which the pancreatic islet cells are destroyed is not well 
understood, several risk factors and immune-related markers are known that accurately identify most of 
the subjects who will develop the disease. Identification is a prerequisite for any intervention aimed at 
delaying or preventing manifestation of the disease, and it becomes all the more important the longer the 
intervention trials and the larger the cohorts are. Three variables are commonly used to express the 
predictive characteristics of a marker. Sensitivity denotes the number of subjects in a cohort with the 
disease and with the marker in question divided by the overall number of subjects who develop the 
disease, whereas specificity is the number of the subjects in a cohort without that marker in question 
who will not develop the disease divided by the total number of subjects who will not do so. Thus a 
reciprocal relationship exists between sensitivity and specificity in a given assay. Positive predictive 
value (PPV) provides information on what proportion of the subjects in a cohort with the marker in 
question will progress to the disease, and is dependent on the prevalence of the disease in the population 
tested. Assessment of the risk of developing type 1 diabetes is currently based on the occurrence of 
autoantibodies and the presence of genetic and metabolic markers. Of all the autoantibody specificities 
identified, ICA, IAA, GADA and IA-2A are regarded at present as clinically the most useful for 
predicting the risk of type 1 diabetes in first-degree relatives of affected patients, but their predictive 
characteristics in the general population, from which about 90% of the newly diagnosed patients are 
derived, still have to be defined more precisely.  
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2.2.5.1 First-degree relatives 
2.2.5.1.1 Humoral risk markers 
ICA positivity is the most sensitive single antibody marker among unaffected family members of 
children with type 1 diabetes, as it identifies approximately 80% of those who will progress to the 
clinical disease. Taken alone, ICA above the detection limit are associated with a relatively low disease 
risk, the PPV varying from 40 to 60% within 9-11 years of follow-up (Kulmala et al. 1998, Yamamoto 
et al. 1998). The risk of progression is related to the titre (Bingley et al. 1994, Kulmala et al. 1998). In a 
birth cohort of 1353 offspring of affected parent(s), ICA above the detection limit identified all the 
children who progressed to clinical disease by 8.5 years and 70% of those who presented with multiple 
autoantibodies during the follow-up (0.1-8.5 years, median 0.9 years) (Ziegler et al. 1999). 
The diagnostic sensitivity of IAA for identifying siblings of diabetic children who will progress to 
clinical disease is relatively low; 25-58% (Kulmala et al. 1998, Yamamoto et al. 1998), while among 
younger subjects 92-100% of those who developed the clinical disease by the age of 8.5 years or 
multiple autoantibodies during the follow-up tested positive for IAA (Ziegler et al. 1999, Colman et al. 
2000).  
The presence of IA-2A among first-degree relatives indicates a high risk of progression to the 
clinical disease, the reported PPV ranging from 50 to 80%, with a sensitivity from 56 to 69% (Kulmala 
et al. 1998, Yamamoto et al. 1998, Decochez et al. 2002). IA-2A were detected in 77-100% of the 
children who developed the clinical disease by the age of 8.5 years and 68-78% of those who presented 
with multiple autoantibodies during the follow-up (Ziegler et al. 1999, Colman et al. 2000). More rapid 
progression to clinical disease has been reported in IA-2A-positive siblings carrying the HLA-DQ2/8 
genotype (Kulmala et al. 2000b, Decochez et al. 2002).  
Multiple antibodies, i.e. at least two antibodies, confers a risk of disease progression in the range 55-
100% in siblings of diabetic patients within a follow-up of 8-13 years, while positivity for a single 
autoantibody carries a risk of only 2-17% (Kulmala et al. 1998, Yamamoto et al. 1998). The detection of 
multiple antibodies by the age of 2 years in the offspring of parent(s) with type 1 diabetes was associated 
with a 50% risk of overt diabetes by five years of age, the cumulative risk in the whole cohort being 
1.8% by that age (Ziegler et al. 1999). In another birth cohort study all the children who presented with 
clinical disease before the age of 4 years tested positive for multiple antibodies before the diagnosis 
(Colman et al. 2000). 
2.2.5.1.2 Genetic markers 
While the risk of contracting type 1 diabetes in Finland by 15 years of age is about 0.7%, that conferred 
by the high-risk genotype, DQB1*0201/*0302, is on average 7% and that conferred by the moderate-
risk genotype, DQB1*0302/x (x= other than *0201, *0301 or *0602), is approximately 2.5% (Ilonen et 
al. 1996). The siblings of affected subjects have been estimated to have an absolute lifetime risk in the 
range of 6-8%, being 16-20% in HLA-identical siblings, 6-8% in HLA-haploidentical siblings and less 
than 1% in HLA-non-identical siblings (Platz et al. 1981, reviewed by Eisenbarth 1986, Tarn et al. 1988, 
Deschamps et al. 1992). The cumulative risk of diabetes is markedly higher among the siblings of 
probands diagnosed before the age of five years (Gillespie et al. 2002).  
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Strong genetic susceptibility predisposes children to early-onset beta-cell autoimmunity (Ziegler et 
al. 1999, Colman et al. 2000) and to presentation with the clinical disease at an early age (Pugliese et al. 
1995, Ilonen et al. 1996, Komulainen et al. 1999, Gillespie et al. 2002). Lower frequencies of ICA, 
GADA, IA-2A and multiple autoantibodies have been observed in unaffected siblings carrying the 
protective DR2 or DQB1*0602 alleles than in other siblings of children with type 1 diabetes (Kulmala et 
al. 2000b), although the protective effect of DR2 is not absolute even for the development of clinical 
disease (Pugliese et al. 1995, Kulmala et al. 2000b). 
2.2.5.1.3 Metabolic risk markers 
The first-phase insulin response (FPIR) in an intravenous glucose tolerance test (IVGTT), which reflects 
the discharge of the contents of the releasable pool of insulin-containing granules bound to the plasma 
membrane of beta cells (Daniel et al. 1999) is currently the best available in vivo method for assessing 
the insulin secretory capacity of these cells. A reduced FPIR has been widely shown to be associated 
with multiple autoantibody positivity, i.e. with signs of extensive humoral autoimmunity against beta-
cell structures, and with a high risk of progression to clinical disease. In the data set on first-degree 
relatives of diabetic patients with ICA > 5 JDFU compiled in the large Islet Cell Antibody Register 
Users Study (ICARUS), those with a FPIR< 50 mU/l were reported to have an up to 85% risk of 
progression to clinical diabetes over the next 5 years, the risk for those with a FPIR in the range 50-100 
mU/l being 50% and that for subjects with FPIR> 100 mU/l only 17%. The prognostic significance of a 
low FPIR was shown to be modified by other risk determinants, e.g. its PPV was increased by a high 
ICA titre and young patient age (Bingley et al. 1996).  
HLA identity and the DQB1 high-risk genotype have been observed to be associated with a 
decreased FPIR in non-diabetic ICA and/or IAA-positive siblings of affected children (Veijola et al. 
1995), while carriers of the DQB1*0602 allele are not protected from the autoimmune process, since 
29% of the ICA-positive relatives carrying DQB1*0602 were shown to have IAA or low FPIR 
(Greenbaum et al. 2000).  
A decrease in FPIR, the earliest metabolic abnormality during the preclinical disease process, is 
regarded as a sign of advanced beta-cell destruction, i.e. late prediabetes (Srikanta et al. 1984, Vialettes 
et al. 1988, Vardi et al. 1991, Herskowitz-Dumont et al. 1993), although the rate of beta-cell destruction 
and prediction of the time to diagnosis on an individual level still are controversial issues (Robert et 
al.1991, Knip et al. 1994). A normal FPIR does not exclude the possibility of rapid progression to 
clinical disease (Robert et al. 1991). 
2.2.5.2 The general population 
2.2.5.2.1 Humoral risk markers 
Reports concerning the predictive value of ICA positivity among children in the general population have 
been controversial so far. The PPV has been estimated to be in the range 0.5 to 6% within 4-7 years of 
follow-up (Lévy-Marchal et al. 1995, Knip et al. 1998), while two prospective surveys carried out in 
Florida and the Netherlands have reported a PPV of 18-50% within 8-11 years of follow-up, implying 
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that ICA could predict type 1 diabetes equally efficiently as in first-degree relatives (Bruining et al. 
1989, LaGasse et al. 2002). The sensitivity was reported to be 57 and 100% in the two studies. The risk 
appears to increase with rising ICA titres (Karjalainen 1990). 
IAA positivity have been reported to yield a sensitivity of 5% and a specificity of 97% in the general 
population (Hagopian et al. 1995), while the PPV has been observed to be 5% (Landin-Olsson et al. 
1992, Bingley et al. 1997). Isolated GADA or IA-2A positivity has been estimated to confer a risk of 5 
to 7% for progression to type 1 diabetes over an interval of 10 years among schoolchildren (Bingley et 
al. 1997). 
Multiple autoantibodies, i.e. two or more, by 14 years of age have been reported to confer a PPV of 
19-50% over a follow-up period of 5-8 years, with a sensitivity of 100% (Kulmala et al. 2001, LaGasse 
et al. 2002). Among genetically susceptible young children derived from the general population who 
persistently tested positive for more than one autoantibody by the age of 2 years and/or progressed to 
clinical type 1 diabetes by the age of 5 years, the sensitivity of ICA was found to be 80%, that of IAA 
93%, that of GADA 60% and that of IA-2A 40%. The respective figures for specificity were 99%, 97%, 
100% and 100% (Kimpimäki et al. 2002). 
2.2.5.2.2 Genetic risk markers 
The predictive value of HLA-DR or DQB1 risk markers in the background population is dependent on 
the national incidence of type 1 diabetes. Accordingly, the absolute risk attached to the high-risk 
genotype, DQB1*0201/*0302, is substantially higher in Finland than in Greece, for instance. Rewers et 
al. (1996) reported that the high-risk genotypes DR3/4 and DQB1*0201/0302 confer a 6.3% risk of 
developing diabetes by 20 years of age in Colorado, USA. Kulmala et al. (2001) genotyped 600 healthy 
schoolchildren and found that 7/9 subjects with three or more autoantibodies carried either the 
DQB1*0302 or the DQB1*02 risk allele while three subjects had a protective genotype. In a study by 
LaGasse et al. (2002), five out of six progressors were observed to carry HLA-conferred susceptibility to 
type 1 diabetes.  
A cohort identified by typing for HLA-DQB1 alleles to be followed up from birth for the appearance 
of beta-cell autoimmunity accounted for 10-15% of the total birth cohort and can be estimated to include 
65-80% of the future patients who will present with type 1 diabetes before reaching adulthood (Knip 
2002). 
2.2.5.2.3 Metabolic risk markers 
An impaired FPIR has been shown to be associated primarily with positivity for multiple autoantibodies 
in cohorts representing the general population (Strebelow et al. 1999, Kulmala et al. 2000, Keskinen et 
al. 2002). In a series of studies on schoolchildren representing non-familial prediabetes, Strebelow et al. 
(1999) observed a reduced FPIR in 10 out of 17 children tested among 22 with multiple high-titre 
autoantibodies. Six out of the 22 children progressed to clinical type 1 diabetes within 46 months. A 
decreased FPIR (< 5th percentile in 129 healthy controls) was seen in four prediabetic children, while 
two progressors had no IVGTT. A Finnish group has recently shown very low FPIRs shortly after 
seroconversion to autoantibody positivity in young children with HLA-DQB1-conferred susceptibility to 
type 1 diabetes, suggesting that the autoimmune-mediated destruction of beta cells may occur early in 
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the course of prediabetes, at least in young children (Keskinen et al. 2002), as assumed previously by 
Bingley et al. (1996).  
2.2.6 Therapeutic aspects 
Strategies for preventing type 1 diabetes can be classified into three categories depending on the stage of 
disease. Primary prevention aims at intervening in exposures that may initiate the disease process before 
any signs of autoimmunity appear, by identifying the subjects at risk based on a positive family history 
and/or disease-associated genetic markers, for example. Secondary prevention aims at delaying and 
possibly suppressing an on-going progressive beta-cell destruction in normoglycaemic subjects with 
signs of beta-cell autoimmunity. Tertiary prevention is initiated after the clinical manifestation and aims 
at preventing secondary complications of the disease by preserving or even restoring beta-cell function. 
Beta-cell regeneration, indeed, may be possible even after the clinical presentation since beta-cell 
autoimmunity has been shown to remain detectable for years in the majority of the patients affected by 
type 1 diabetes (Savola et al. 1998b). Preservation of residual beta-cell function is measured in terms of 
circulating C-peptide levels. Tertiary interventions are usually the first approaches to test the efficiency 
and safety of an intervention strategy, particularly if the preventive measure may have potential toxic 
effects. 
Several immunosuppressive drugs have been tested for diabetes prevention, e.g. cyclosporin 
(Bougneres et al. 1988). A disadvantage of these drugs is that they unselectively suppress protective 
immune functions. The majority of the on-going and planned trials are designed to restore 
immunological tolerance of beta-cell antigens, e.g. by mucosal administration of insulin. 
Immunomodulation is yet another way to induce a beta-cell rest; monoclonal antibodies against cell 
surface proteins or against chemokines interfering with T-cell activation or inducing proliferation of 
regulatory T cells have been proposed for testing in prevention trials.  
2.2.6.1 Primary prevention  
The Trial to Reduce IDDM in Genetically at Risk (TRIGR) is an international randomized multicentre 
intervention trial designed to determine whether the elimination of cow’s milk proteins during the first 
6-8 months of life will reduce the risk of beta-cell autoimmunity and the incidence of type 1 diabetes in 
genetically high-risk children. A pilot study indicated that such a nutritional intervention in early infancy 
could significantly reduce the cumulative incidence of ICA and positivity for at least one autoantibody 
during observation up to the age of 7 years (Åkerblom et al. in press).  
2.2.6.2 Secondary prevention  
The elimination of dietary gluten has been tested as an attempt to reduce islet autoimmunity in high-risk 
subjects. A gluten-free diet pursued for 6-12 months followed by gluten re-exposure in two separate 
small series of autoantibody-positive subjects did not have any influence on antibody levels (Hummel et 
al. 2002, Pastore et al. 2003). Interestingly, however, the FPIR increased in 12 out of 14 subjects after 
the first 6 months of gluten deprivation and decreased in 10 out of 13 subjects during the following 6-
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month period of a normal diet, indicating that gluten deprivation may have a beneficial effect on the 
preservation of beta-cell function in subjects at risk for type 1 diabetes (Pastore et al. 2003). 
Oral nicotinamide did not reduce the cumulative incidence of type 1 diabetes at 3 years from 30 to 6 
%, i.e. by 80%, in a series comprising very high-risk first-degree relatives in the randomized German 
Nicotinamide Diabetes Intervention Study (DENIS) (Lampeter et al. 1998), although a smaller 
protective effect, 56% after an average follow-up of 7 years, was shown in an open population-based 
survey among schoolchildren in New Zealand (Elliott et al. 1996). The large multinational European 
Nicotinamide Diabetes Intervention Trial (ENDIT) was a randomized, double-blind, placebo-controlled 
survey targeting ICA-positive (> 20 JDFU) first-degree relatives and aimed at reducing the incidence of 
type 1 diabetes by 35% over 5 years. The study was recently completed, and the outcome was 
unfortunately negative: there was no difference what-so-ever between the two groups in terms of 
progression to clinical diabetes (ENDIT Study Group 2004).  
The American Diabetes Prevention Trial-Type 1 Diabetes (DPT-1) is a multicentre two-arm 
intervention trial, the first part of which has tested parenteral administration of insulin for preventing 
type 1 diabetes by 50% within 4 years in first and second-degree relatives with >ICA 10 JDFU and a 
reduced FPIR (<10th percentile). This part showed no difference in the rate of progression to overt type 1 
diabetes between the subjects treated and the control group (DPT-1 Study Group 2002). The second part 
was an assessment with a randomized, double-blinded design of whether daily oral administration of 
insulin could reduce the incidence of type 1 diabetes in ICA-positive subjects with a normal FPIR by at 
least 25% over 4 years. The preliminary results presented at the 2003 American Diabetes Association 
Scientific Meeting indicated that there was again no difference in the cumulative incidence of type 1 
diabetes between the insulin-treated group and the placebo group.  
In the DIPP project nasal insulin is being tested in a randomized placebo-controlled trial with 
autoantibody-positive children having HLA-conferred susceptibility to type 1 diabetes (Kupila et al. 
2001). This trial will be completed by the end of 2006. 
2.2.6.3 Tertiary prevention  
Although the residual beta-cell mass is already small at a time of clinical onset of type 1 diabetes, the 
trials with immunosuppressive drugs have shown that the course of beta-cell function can still be 
modified at this phase. Oral insulin initiated at clinical presentation did not prevent the deterioration of 
beta-cell function in a multicentre randomized double-blind intervention trial (Chaillous et al. 2000), nor 
in an Italian randomized placebo-controlled trial (Pozzilli et al. 2000). Nicotinamide has been observed 
to preserve some C-peptide secretion in patients with newly diagnosed type 1 diabetes (Pozzilli 1996). 
Treatment with a 14-day course of intravenous human anti-CD3 monoclonal antibody resulted in 
improved preservation of endogenous insulin secretion after a follow-up for 12 months in a randomized 
open trial (Herold et al. 2002). 
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3 Aims of the present research 
The specific aims of this work were: 
 
I. to define the relationship between circulating concentrations of sICAM-1 and sL-selectin and 
genetic susceptibility to type 1 diabetes conferred by HLA class II alleles. 
 
II. to define the relationship between type 1 diabetes-associated autoantibodies and circulating 
levels of sICAM-1 and sL-selectin. 
 
III. to investigate the circulating concentrations of sICAM-1 and sL-selectin in subjects with 
impaired insulin secretory capacity. 
 
IV. to follow-up the circulating levels of sICAM-1 and sL-selectin during preclinical type 1 diabetes 
in first-degree relatives of affected children and in young children with genetic susceptibility to 
type 1 diabetes, and to assess the utility of these molecules as potential surrogate markers of the 
disease. 
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4 Subjects and methods 
4.1 Subjects 
4.1.1 Publications I and II 
The subjects referred to in publications I and II were derived from the nationwide Childhood Diabetes in 
Finland (DiMe) study (Tuomilehto et al. 1992), which is a prospective, population-based family survey 
initiated at the beginning of September 1986 to investigate the role of genetic, immunological and 
environmental factors in the development of type 1 diabetes. All children aged 15 years or younger with 
newly diagnosed type 1 diabetes, their siblings under 20 years of age and their parents were invited to 
participate. By the end of April 1989, 801 index cases had been diagnosed and 977 unaffected siblings 
had been recruited for a prospective study. The first blood sample from each sibling was obtained at or 
close to the diagnosis of the index case and subsequent samples were taken at intervals of 3-6 months 
over the first 2 years and at intervals of 12 months thereafter for up to 4 years. The siblings were 
observed up to the end of December 1998, unless type 1 diabetes was diagnosed before that date. 
Diagnosis was based on clinical symptoms and an increased random blood glucose concentration 
(>10mmol/l), or elevated fasting blood glucose (>6.7mmol/l), or random blood glucose >10mmol/l on 
two occasions in the absence of symptoms (WHO Study Group 1985). There were 755 siblings (77.3%) 
with at least one blood sample available. The first sample for each of the siblings was analysed for islet 
cell antibodies (ICA), insulin autoantibodies (IAA) and antibodies to the 65 kDa isoform of glutamic 
acid decarboxylase (GADA) and the protein tyrosine phosphatase-related IA-2 antigen (IA-2A).  
The subjects considered in publication I included all 95 siblings whose initial sample was positive 
for at least one autoantibody out of the four analysed, while the control group comprised 95 sex and age-
matched (± 6 months) siblings who remained antibody-negative throughout the follow-up. The mean age 
of the cases was 9.8 years (range 1.1-18.9) and that of the controls similarly 9.8 years (range 1.4-18.6).  
The levels of sICAM-1 and sL-selectin were measured in the first blood sample available, these samples 
having been stored at –20°C or below until analysis. Twenty-nine autoantibody-positive siblings had 
progressed to clinical type 1 diabetes by the end of 1997. 
The subjects discussed in publication II included all 39 siblings who were positive for at least one of 
the four diabetes-associated autoantibodies on at least one occasion during the 4-year follow-up period 
and had progressed to clinical type 1 diabetes during prospective observation for a median 10.7 years 
(range 9.7-12.3 years) between September 1986 and the end of December 1998.Thirty-nine 
autoantibody-positive siblings who remained non-diabetic, were matched with them for sex, age (± 2 
years in 90% of the subjects) and the initial number of autoantibodies (the same number in nine subjects, 
± one antibody in 14 subjects, ± two antibodies in 11 subjects and ± three antibodies in five subjects) to 
serve as a control group. Autoantibodies and soluble adhesion molecules were measured in sequential 
follow-up samples. There were 19 boys and 20 girls in each group. The median age of the siblings at 
recruitment was 7.4 years for the progressors (range 1.5-16.4 years) and 7.6 years for the non-
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progressors (range 1.1-16.5 years). The median duration of follow-up from the initial blood sampling to 
diagnosis was 4.4 years (range: 9 days-11.7 years). A subgroup of the initial one comprised 30 sibling-
pairs matched for the duration of follow-up in addition to age, sex and the initial number of antibodies. 
The mean follow-up time for these was 3.0 years (range 0.2-5.7 years) among the progressors and 2.9 
years (range 0.2-6.2 years) among the non-progressors. A total of 345 serum samples were analysed for 
sICAM-1 and 344 samples for sL-selectin, the number of samples per sibling varying from one to nine 
(median 4.6 for the progressors and 4.5 for the non-progressors).  
4.1.2 Publication III 
The study of beta-cell autoimmunity in schoolchildren in northern Finland was initiated at the beginning 
of 1994, when all 7 to 16-year-old schoolchildren (n=4280) living in five municipalities in the province 
of Oulu were invited to take part (Kulmala et al. 2000a). 3652 non-diabetic schoolchildren were 
included and were analysed for islet cell antibodies and for antibodies to glutamic acid decarboxylase, of 
whom 106 (2.9%) tested positive for one or both in their initial sample. These children (the cases), 
except for two subjects who had progressed to clinical diabetes before the re-examination, were invited 
to the second part of the study which included blood sampling for autoantibody determinations (ICA, 
IA-2A, GADA and IAA), an intravenous glucose tolerance test (IVGTT) and more recently analyses for 
the soluble adhesion molecules sICAM-1 and sL-selectin. In addition, 104 initially autoantibody-
negative children matched with the cases for age, sex and place of residence were inivited as controls.  
There were 51 boys and 53 girls in the group of autoantibody-positive children and their mean age at 
the time of the IVGTT was 13.7 years (range 9.4-18.8 years). Two of the antibody-positive subjects had 
a first-degree relative with type 1 diabetes, an affected father in one case and an affected mother in the 
other, while none of the control children had an affected family member. The children were observed for 
progression to clinical diabetes from the time of the second sampling to the end of May 1999, a mean 
period of 3.4 years (range 3.2-3.6 years), using as a source the Central Drug Register of the Social 
Insurance Institute, which records more than 99% of all new cases of type 1 diabetes (Reunanen A, 
personal communication). There were two initially healthy schoolchildren who progressed to manifest 
diabetes during the observation period: a boy whose sample was taken at the age of 10.7 years, 2.7 years 
before diagnosis, and a girl whose sample was taken at the age of 10.8 years, 1.4 years before diagnosis. 
Both of them were positive for multiple autoantibodies, had FPIR values below the 1st percentile and 
were significantly younger than the non-progressors: 9.1 years vs 11.6 years (p=0.05). The boy carried 
the DQB1*0301/*0603 genotype and the girl had the DQB1*02/*0602 genotype (Kulmala et al. 2000a). 
4.1.3 Publication IV 
The Finnish Type 1 Diabetes Prediction and Prevention (DIPP) study was established to refine 
prediction in the general population and to develop effective strategies to prevent or delay progression to 
clinical disease. The strategy is based on the identification of HLA-DQB1-conferred genetic 
susceptibility in infants born at the university hospitals in Turku, Oulu and Tampere and follow-up for 
the appearance of signs of beta-cell autoimmunity (Kupila et al. 2001). The study also includes an 
intervention programme targeting children with permanent autoantibody positivity. The objective is to 
test in a randomized, double-blind, placebo-controlled trial whether daily intra-nasal administration of 
insulin can prevent or delay the clinical onset of type 1 diabetes.  
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All the 130 children included in the series in publication IV were carriers of the high-risk genotype 
DQB1*02/*0302 or the moderate-risk genotype DQB1*0302/x (x= other than *02, *0301 or *0602). To 
monitor for beta-cell autoimmunity, blood samples were obtained at 3 and 6 months and subsequently at 
intervals of 3-6 months during the first 2 years and intervals of 6-12 months thereafter, using islet cell 
antibodies (ICA) as the primary screening test. If autoantibodies were detectable at the age of 3 or 6 
months the cord blood sample was also analysed for ICA, IAA, GADA and IA-2A. Samples with 
decreasing titres of autoantibodies for infants who also had autoantibodies in their cord sample were 
regarded as maternal and excluded from the analysis. The subjects comprised the 65 children who tested 
positive for ICA at least once before their fourth birthday (median age 18 months, range 6-36 months) 
by the end of May 1999 (Kimpimäki et al. 2001a) and 65 control children without diabetes-associated 
autoantibodies matched with the cases for sex, DQB1 genotype, geographical region and date of birth, as 
closely as possible, with a median difference of 7 days. The levels of soluble adhesion molecules were 
quantified in sequential follow-up samples of these subjects with a median duration of the total follow-
up period of 24 months (range 13-37 months) for the autoantibody-positive children and 24 months 
(range 6-36 months) for the control children. 
Twenty-one children progressed to clinical type 1 diabetes before the age of 5 years during the 
observation period, i.e. up to the end of December 2003, thirteen doing so before the age of 3 years and 
the remainder between 3 and 4.9 years. 
4.2 Methods 
4.2.1 Autoantibody assays (I, II, III, IV) 
Autoantibodies were analysed in the Research Laboratory, Department of Paediatrics, University of 
Oulu. ICA levels were determined by a standard immunofluorescence method using sections of frozen 
human blood group 0 pancreas (Bottazzo et al. 1974). All sera with detectable ICA were titrated to end-
point dilution, and the results were expressed in Juvenile Diabetes Foundation Units (JDFU). The 
detection limit was 2.5 JDFU, and all samples positive for ICA initially were retested for confirmation. 
The sensitivity of the ICA assay was 100% and the specificity 98% in the fourth round of the 
international workshop on the standardization of the ICA assay (Greenbaum et al. 1992).  
Autoantibodies to GAD65 (GADA) were quantified in publications I-III with a radiobinding assay as 
described by Petersen et al. (1994) and Sabbah et al. (1996), while a slightly modified radiobinding 
assay was used in publication IV (Savola et al. 1998a). The results were expressed in relative units (RU). 
The cut-off for GADA was 6.6 RU initially and 5.36 RU in the modified assay, these limits representing 
the 99th percentile in more than 370 non-diabetic Finnish children and adolescents. Autoantibodies to 
IA-2 (IA-2A) were analysed with a radiobinding assay described by Bonifacio et al. (1995) and Savola 
et al. (1998a). The cut-off limit for autoantibody positivity was 0.43 RU (the 99th percentile in 374 non-
diabetic children and adolescents). The disease sensitivity of the initial GADA assay was 79% and the 
specificity 97%, based on 140 samples derived from the 1995 Multiple Autoantibody Workshop (Verge 
et al. 1998), whereas the sensitivity of the modified GADA assay was 82% and the specificity 98% in 
the Diabetes Antibody Standardization Programme (DASP) Workshop 2002. The disease sensitivity and 
specificity of the IA-2A assay were 62 and 100%, respectively, in the DASP 2002 Workshop. 
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IAA levels were quantified in publications I and II with a radiobinding assay modified from that 
described by Palmer et al. (1983) and expressed in nU/ml, where 1 nU/ml corresponds to a specific 
binding of 0.01% of the total counts. A subject was considered to be positive for IAA when specific 
binding exceeded 54 nU/ml (99th percentile in 105 non-diabetic children and adolescents). The disease 
sensitivity of our IAA assay was 26% and the specificity 97%, based on 140 samples derived from the 
1995 Multiple Autoantibody Workshop (Verge et al. 1998).  
In publications III and IV, IAA levels were measured with a radioligand microassay on 96-deep-well 
plates (Ronkainen et al. 2001), a modification of the radiobinding assay described by Williams et 
al.(1997), and expressed in relative units based on a standard curve run on each plate using the 
MultiCalc software (PerkinElmer Life Sciences Wallac, Turku, Finland). A subject was considered 
positive for IAA when the specific binding exceeded 1.55 RU (99th percentile in 371 non-diabetic 
Finnish subjects). The disease sensitivity of our microassay was 44% and the specificity 98% in the 
2002 DASP Workshop. 
 
4.2.2 Intravenous glucose tolerance test (I, III) 
IVGTTs were performed after a preceding fast of 10-16 h by infusing 0.5 g glucose/kg body weight in a 
20% solution intravenously over a period of 3 min ± 15 s. The FPIR to glucose was defined as the sum 
of the 1 and 3-min serum insulin concentrations. Blood glucose levels were quantified by the glucose 
oxidase method (Hjelm 1966). 
For publication I, IVGTTs were performed on 49 autoantibody-positive siblings during the follow-
up, with blood samples taken before the infusion (0 min) and 1, 3, 6, 10, 20, 30, 40, 50 and 60 min after 
its completion. Serum insulin concentrations were measured by radioimmunoassay (Herbert et al. 1965). 
FPIR levels < 45 mU/l, which correspond to the 3rd percentile of FPIR values measured in healthy 
control subjects (Srikanta et al. 1984), were considered abnormally low. This limit was defined after 
correction for assay differences on the basis of an insulin standardization round within the ICARUS 
survey.  
The IVGTTs reported in publication III were performed according to the ICARUS protocol (Bingley 
et al. 1992). Blood samples were taken 5 and 0 minutes before the infusion and 1, 3, 5 and 10 minutes 
after it had been completed. Serum insulin concentrations were measured with an ELISA (Andersen et 
al. 1993) having a sensitivity of 0.5 mU/l and intra-assay and inter-assay coefficients of variation less 
than 7.5% and 9.3%, respectively. The percentile values for the FPIR in the 103 control children were: 
1st percentile 29.5 mU/l, 2.5th percentile 35.0 mU/l, 5th percentile 45.0 mU/l and 10th percentile 52.1 
mU/l (Kulmala et al. 2000a). 
4.2.3 Soluble adhesion molecule assays (I, II, III, IV) 
sICAM-1 and sL-selectin concentrations were analysed with specific ELISA kits according to the 
manufacturer’s instructions (Bender Medsystems Diagnostics GmbH, Vienna, Austria). The assays are 
based on two monoclonal antibodies directed against different epitopes on the soluble adhesion 
molecules. Diluted serum samples (1:10 for sICAM-1 and 1:200 for sL-selectin) were added in 
duplicates to the microtitre wells, which were precoated with murine Mab to human ICAM-1 or L-
selectin. A second horseradish peroxidase-conjugated murine Mab was then added to bind a second 
 39
epitope on the molecule captured by the first antibody, and the plates were incubated at room 
temperature for 1 hour in the ICAM-1 assay and for 2 hours in the L-selectin assay. After thorough 
washing to remove the unreactive component, 3,3,5,5-tetramethylbenzidine was added to the wells to 
form a coloured end product and the plates were incubated for an additional 15 minutes. A coloured 
product is formed in proportion to the amount of soluble ICAM-1/L-selectin present in the sample. The 
reaction was stopped by adding phosphoric acid and the absorbances were measured at a wavelength of 
450 nm with a Multiscan MS photometer (Labsystems, Helsinki, Finland). The results were read from a 
standard curve (prepared from standard dilutions of sICAM-1/sL-selectin). The coefficients of intra-
assay and inter-assay variation were less than 5% and less than 8% for sICAM-1 and less than 4% and 
less than 5%, respectively, for sL-selectin.  
When sICAM-1 and sL-selectin levels were determined after aliquots of serum samples had been 
stored at -20ºC and thawed several times there was no significant loss of their concentrations between 0 
and 5 freeze-thaw cycles. Likewise, when aliquots of a serum samples were stored at -20ºC, 2-8ºC, room 
temperature and +37ºC and sICAM-1 was determined after 24, 48 and 96 hours and sL-selectin after 24 
hours there was no significant loss of their immunoreactivity.  
 
4.2.4 HLA typing (I, III) 
HLA-DR alleles were typed for publication I using conventional HLA serology, as described by 
Tuomilehto-Wolf et al. (1989). T and B lymphocytes were isolated by means of a Percoll centrifugation 
gradient during the first year of the DiMe study and with immunomagnetic beads (Dynabeads, Dynal, 
Oslo, Norway) coated with monoclonal antibodies against class I or class II antigens from September 
1987 onwards. HLA antiserum to recognize all HLA-A, B, C and DR specificities was used in the test 
panel, according to the 1984 recommendations of the Nomenclature Committee of the WHO. 
HLA-DQB1 alleles were defined in publication III by a previously described method based on a 
polymerase chain reaction (PCR) (Sjöroos et al. 1995). Four sequence-specific probes were used to 
identify the DQB1 alleles known to be associated with either susceptibility to or protection against type 
1 diabetes in the Finnish population: DQB1*0302, DQB1*02, DQB1*0602 or 0603, and DQB1*0301 
(Ilonen et al. 1996). All DQB1*02-positive samples were further analysed for the presence of DQA1*05 
or DQA1*0201 alleles to differentiate between the DQA1*05-DQB1*02 (DR3) and DQA1*0201-
DQB1*02 (DR7) haplotypes (Sjöroos et al. 1998). We used the previously described simplified 
classification of DQB1 genotypes into high risk: DQB1*02/*0302, moderate risk: DQB1*0302/x (x 
stands for *0302 or a non-defined allele), low risk: DQB1*0301/*0302, DQB1*02/*0301, DQB1*02/x, 
DQB1*0302/*0602 or*0603 (x stands for *02 or a non-defined allele) and decreased risk: DQB1 *x/x, 
DQB1*0301/x, DQB1*02/*0602 or *0603, DQB1*0301/*0602 or *0603 (x stands for a non-defined 
allele) (Ilonen et al. 1996). 
4.2.5 Enterovirus infections (IV) 
Enterovirus infections were diagnosed in publication IV from serial serum samples by antibody 
measurements and detection of viral RNA. IgG and IgA-class antibodies were measured using an 
indirect enzyme immunoassay (EIA) against purified coxsackie B4 virus, purified echovirus 11 and a 
synthetic enterovirus peptide antigen (Lönnrot et al. 2000). In addition, IgM and IgA-class antibodies 
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against a mixture of three enterovirus antigens (coxsackie B3 virus, coxsackie A16 virus and echovirus 
11) were analysed using a capture EIA method (Lönnrot et al. 2000). Viral RNA was detected using a 
highly sensitive reverse transcriptase-polymerase chain reaction (RT-PCR) assay that detects practically 
all enterovirus serotypes and was carried out as previously described (Lönnrot et al. 1999). All positive 
samples were confirmed as such by repeated RT-PCR and subsequent hybridization assay. A twofold or 
greater increase in the level of antibodies against an antigen between two consecutive samples and 
exceeding the cut-off level for seropositivity (15 enzyme immune units), or the presence of enterovirus 
RNA in serum was considered an indicator of acute infection (Lönnrot et al. 2000). 
4.2.6 Infant nutrition (IV) 
Data on breast-feeding and the introduction of cow’s milk were recorded at every visit for as long as 
appropriate as described in detail previously (Kimpimäki et al. 2001a). The duration of exclusive and 
overall breast-feeding and the age at which cow’s milk was introduced were assessed for each subject. 
Exclusive breast-feeding was defined as the period for which the infant did not receive any other food 
than breast milk, and the introduction of cow’s milk formula, cow’s milk or other cow’s milk products 
was defined as the age at which feeding with these was initiated. The median duration of exclusive 
breast-feeding in the cases was 1.8 months [25th and 75th percentiles interquartile range (IQR) 0.5-3.9] 
and that in the control children 2.5 months [IQR 0.5-3.5]. The median duration of overall breast-feeding 
in the cases was 6.0 months [IQR 2.9-10.5] and that in control children 6.0 months [IQR 3.0-7.5]. The 
median age at the introduction of cow’s milk was 2.0 months [IQR 0.5-5.0] in the cases and 2.5 months 
[IQR 0.5-5.2] in the control children. 
4.2.7 Data handling and statistical analyses  
4.2.7.1 Data handling 
The visual inspection of the individual soluble adhesion molecule profiles in the work for publications II 
and IV was complemented with a summary measure approach to compare the integrated concentrations 
over time between the groups (Matthews et al. 1990), the total quantity of soluble adhesion molecules 
being expressed as the area under the curve (AUC). In addition, each sibling discussed in publication II 
was also analysed for his/her lowest (nadir) and highest (peak) measured concentrations of sICAM-1 
and sL-selectin. The siblings were divided into antibody-positive and negative subgroups based on the 
antibody status in the first available sample when analysing integrated concentrations or when analysing 
nadir ad peak concentrations during the follow-up. 
We also calculated the mean concentrations of soluble adhesion molecules over 3-month periods for 
each subject in publication IV in relation to initial seroconversion and signs of enterovirus infections 
(EVI), where initial seroconversion refers to the first appearance of autoantibodies irrespective of the 
antibody specificity. The levels during such periods were first compared separately among the cases and 
the controls, and then the concentrations in the cases were compared with those in the controls for each 
period. If more than one enterovirus infection was detected during the observation period among the 
cases, the one closest to seroconversion to autoantibody positivity (or the earlier one if two infections 
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were at equal distance) was chosen. Among the controls the temporally closest enterovirus infection to 
that in the respective case was chosen. The median age at the detection of an enterovirus infection was 
12 months (range 6-24 months) in the autoantibody-positive children and similarly 12 months (range 3-
24 months) in the control children. 
4.2.7.2 Statistical analyses 
 
The data are presented as means (SD) or medians and interquartile ranges [IQR i.e. the 25th and 75th 
percentiles]. Normally distributed continuous data were analysed with the t-test or ANOVA. An analysis 
of covariance was used, after logarithmic transformation in the case of skewed distributions, to adjust 
for the effect of age on the circulating concentrations of soluble adhesion molecules. In the case of 
skewed distributions the Mann-Whitney U-test or the Kruskall-Wallis one-way analysis of variance was 
used for group comparisons. Correlations were tested either with linear regression analysis (r) or with 
Spearman’s non-parametric correlation analysis (rs). The Bonferroni adjustment for multiple 
comparisons was used when appropriate. A two-tailed p-value of 0.05 or less was considered 
statistically significant.  
All the statistical analyses were performed using the SPSS statistical software package for Windows 
(SPSS Inc., Chicago, Illinois, USA). 
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Table 3. Subjects and study design in the four publications. 
Publication Design Subjects N Variables 
I A cross-sectional case- 
control study within a 
prospective cohort study 
Autoantibody-
positive siblings 
of children with 
recent-onset type 
1 diabetes (cases) 
95 HLA-DR 
phenotype, 
autoantibodies, 
FPIR, 
progression to 
type 1 diabetes 
 
  Autoantibody-
negative siblings 
of children with 
recent-onset type 
1 diabetes 
(controls) 
 
95  
II A longitudinal case-
control study within a 
prospective cohort study 
Autoantibody-
positive siblings 
of children with 
recent-onset type 
1 diabetes (cases) 
 
39  Progression to 
type 1 diabetes 
  Autoantibody-
positive siblings 
of children with 
recent-onset type 
1 diabetes 
(controls) 
 
39  
 
 
III A cross-sectional 
population-based case-
control study 
Autoantibody- 
positive school- 
children (cases)  
104 HLA-DQB1 
genotype, 
autoantibodies, 
FPIR, 
progression to 
type 1 diabetes 
  Autoantibody-
negative 
schoolchildren 
(controls) 
 
104  
IV A nested longitudinal 
case-control study within 
a population-based 
prospective birth cohort 
study  
Genetically 
susceptible 
children who 
converted to 
autoantibody 
positivity during 
a follow-up from 
birth (cases) 
65 Seroconversion, 
enterovirus 
infections, 
early infant diet, 
progression to 
type 1 diabetes 
 
  Genetically 
susceptible 
children who 
remained 
autoantibody-  
negative during  
a follow-up from 
birth (controls) 
65  
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5 Results 
5.1 Soluble adhesion molecules in relation to sex and age (I, III) 
A negative correlation was observed between age and the circulating concentrations of both sICAM-1 
(r=-0.31, p<0.001) and sL-selectin (r=-0.27, p<0.001) among the control siblings, and the sICAM-1 and 
sL-selectin concentrations were interrelated (r=0.46, p<0.001). The sL-selectin level correlated inversely 
with age (rs=-0.36, p<0.001), whereas the sICAM-1 concentrations were not significantly related to age 
(rs=-0.07, p=0.49) among the control schoolchildren. The circulating levels of sICAM-1 and sL-selectin 
did not correlate among the control schoolchildren (rs=-0.02, p=0.87).  
The concentrations of soluble adhesion molecules were similar in the boys and girls among both the 
control siblings and the control schoolchildren (data not shown). 
5.2 Relation of soluble adhesion molecules to HLA class II-conferred 
susceptibility to type 1 diabetes (I, III) 
No relationship was observed between sICAM-1 and sL-selectin levels and the degree of HLA identity 
with the proband (data not shown) or various HLA-DR phenotypes (Fig.1) among the antibody-negative 
siblings of the children with newly diagnosed type 1 diabetes. There was a trend for lower sICAM-1 and 
sL-selectin concentrations in siblings with the HLA-DR3/non-DR4 phenotype than in those who were 
heterozygous for HLA-DR3/4 or carried the DR4/non-DR3 or non-DR3/non-DR4 combinations, but the 
differences remained non-significant for both adhesion molecules. Siblings with the DR2 allele had 
soluble adhesion molecule concentrations similar to those observed in the DR2-negative siblings (data 
not shown). 
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Figure 1. Circulating levels of sICAM-1 (A) and sL-selectin (B) in autoantibody-negative siblings of children with 
recent-onset type 1 diabetes, by HLA-DR phenotype status.  Each box-plot represents the median and the 25th and 
75thpercentiles.  The error bars represent the smallest and largest values that are not outliers. 
 
There was no association between sICAM-1 levels and the DQB1 risk genotypes among the 
antibody-negative schoolchildren, but the subjects carrying genotypes conferring a high or moderate risk 
of type 1 diabetes had lower levels of sL-selectin than those with genotypes associated with a low or 
decreased risk (p=0.04) (Fig.2). We did not find any significant differences in the levels of soluble 
adhesion molecules between the autoantibody-negative subjects with or without the alleles indicating 
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susceptibility to type 1 diabetes, i.e. DQB1*0302 (n=24/79) or DQB1*02 (n=28/75), or between those 
with or without the alleles indicating protection against type 1 diabetes, i.e. DQB1*0602, *0603 
(n=40/63) or DQB1*0301 (n=10/93). Subjects with and without the DQA1*05-DQB1*02 haplotype 
(n=22/81) had the similar soluble adhesion molecule levels (data not shown).  
 
 
Figure 2. Circulating levels of sICAM-1 (a) and sL-selectin (b) in autoantibody-negative schoolchildren, by HLA-
DQB1 genotype status.  Each box-plot represents the median and the 25th and 75thpercentiles.  The error bars 
represent the smallest and largest values that are not outliers. 
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5.3 Relation of soluble adhesion molecules to diabetes-associated 
autoantibodies (I, II, III) 
The autoantibody-positive siblings had a mean serum sICAM-1 concentration of 277 (74;SD) µg/l, 
which was similar to that seen in the autoantibody-negative siblings [279 (78) µg/l]. There was similarly 
no significant difference in serum sL-selectin levels between the two groups [2750 (940) µg/l vs 2720 
(830) µg/l]. 
The autoantibody-positive siblings with high ICA levels (> 20 JDFU) (n= 37) had higher sICAM-1 
concentrations than those with low ICA levels, [314 (82) µg/l vs  254 (59) µg/l; p<0.001], even after 
adjustment for age (p=0.001), while the sL-selectin concentrations were of the same magnitude in these 
two groups [2910 (1010) µg/l vs 2650 (880) µg/l; p=0.192]. Siblings testing positive for IA-2A (n=40) 
had higher sL-selectin and sICAM-1 concentrations than those without detectable IA-2A [sL-selectin 
3010 (1020) µg/l vs  2570 (830) µg/l; p=0.022, and sICAM-1 296 (77) µg/l vs  263 (70) µg/l; p=0.034]. 
There were no significant differences in circulating concentrations of soluble adhesion molecules 
between the siblings testing positive for GADA (n=57) and those who were negative for GADA 
[sICAM-1 288 (79) µg/l vs 259 (64) µg/l; p=0.062, and sL-selectin 2750 (990) µg/l vs 2750 (860) µg/l; 
p=0.996] or between the IAA-positive (n=28) and IAA-negative siblings [sICAM-1 260 (68) µg/l vs 284 
(76) µg/l; p=0.161, and sL-selectin 2660 (930) µg/l vs 2790 (940) µg/l; p=0.533].  
Siblings testing positive for two or more antibodies (n=48) had significantly higher sICAM-1 levels 
than those with only one detectable autoantibody specificity or none at all [297 (83) µg/l vs 272 (72) 
µg/l; p<0.05], without any significant age difference between the groups (p=0.124). A more detailed 
analysis showed increased sICAM-1 concentrations (p=0.006), particularly in those with three or four 
antibodies, relative to those testing positive for only one antibody, without any significant difference in 
age between the groups (p=0.056) (Fig.3A). Siblings with three or four autoantibodies had also higher 
sL-selectin concentrations than those testing positive for two antibodies (p=0.005; Fig.3B).  
No difference was observed in the integrated concentrations of soluble adhesion molecules in 
relation to the initial or maximal number of autoantibodies detected during the follow-up, or when 
analysed according to the autoantibody status among the siblings of the children affected by type 1 
diabetes (data not shown).  
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Figure 3. Circulating levels of sICAM-1 (A) and sL-selectin (B), by the number of autoantibodies, in siblings of 
children with recent-onset type 1 diabetes.  Each box-plot represents the median and the 25th and 75th percentiles.  The 
error bars represent the smallest and largest values that are not outliers. Ab indicates antibody. 
 
The levels of soluble adhesion molecules were comparable between the autoantibody-positive and 
negative initially healthy schoolchildren, and their circulating concentrations were similar in the subjects 
who were positive for ICA, IA-2A, GADA or IAA and those who tested negative for these autoantibody 
specificities (Table 4 and 5). No significant differences were seen between the subjects who were 
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positive for any of the biochemically characterized antigens (IA-2A, GADA or IAA) and those who 
were not, irrespective of ICA status or titre (data not shown). On the other hand, the autoantibody-
positive children with an ICA level of 40 JDFU or more tended to have higher levels of sICAM-1 than 
those with lower ICA titres, although the difference did not reach statistical significance (Table 4).  
 
 
Table 4. Circulating levels of sICAM-1 (μg/l) in 208 non-diabetic schoolchildren, by diabetes-associated 
autoantibody status. The data are expressed as medians and interquartile range (IQR, i.e. 25th and 75th 
percentiles) Ab indicates antibody. 
   Ab-positive  Ab-negative  p-value 
> 1 Ab (n=104/104)  370 (310;440)  390 (300;460)  0.84 
ICA (n=98/110)  370 (320;450)  390 (300;450)  0.72 
ICA > 10 JDFU  370 (320;450)  380 (300;450)  0.39 
versus < 10 JDFU (n=84/124) 
ICA > 20 JDFU  370 (320;440)  380 (300;450)  0.89 
versus < 20 JDFU (n=31/177) 
ICA > 40 JDFU   430 (340;460)  380 (300;440)  0.15 
versus < 40 JDFU (n=15/193) 
IA-2A (n=10/198)  430 (290;470)  370 (310;450)  0.46 
GADA (n=17/191)  390 (290;440)  380 (310;450)  0.81 
IAA (n=7/201)  350 (340;520)  380 (310;450)  0.49 
 
Table 5. Circulating levels of sL-selectin (mg/l) in 208 non-diabetic schoolchildren, by diabetes-associated 
autoantibody status. The data are expressed as medians and (interquartile range (IQR, i.e. 25th and 75th 
percentiles). Ab indicates antibody. 
   Ab-positive  Ab-negative  p-value 
> 1 Ab (n=104/104)  1.79 (1.44;2.16)  1.86 (1.53;2.26)  0.32 
ICA (n=98/110)  1.78 (1.44;2.17)  1.86 (1.55;2.24)  0.34 
ICA > 10 JDFU  1.79 (1.44;2.20)  1.86 (1.53;2.16)  0.65 
versus < 10 JDFU (n=84/124) 
ICA > 20 JDFU  1.80 (1.45;2.17)  1.84 (1.48;2.22)  0.93 
versus < 20 JDFU (n=31/177) 
ICA > 40 JDFU  1.77 (1.44;1.96)  1.86 (1.48;2.22)  0.50 
versus < 40 JDFU (n=15/193) 
IA-2A (n=10/198)  1.90 (1.70;2.10)  1.83 (1.47;2.19)  0.71 
GADA (n=17/191)  1.90 (1.64;2.11)  1.84 (1.47;2.24)  0.92 
IAA (n=7/201)  1.46 (1.16;2.04)  1.86 (1.49;2.20)  0.17 
 
 
 
There was a positive association between sICAM-1 concentrations and IA-2A titres in the IA-2A-
positive children (rs=0.62, p=0.05), but no relationship was seen between sL-selectin concentrations and 
IA-2A or ICA titres, nor between the levels of soluble adhesion molecules and GADA or IAA titres 
(data not shown).  There were no differences in the levels of sICAM-1 or sL-selectin in relation to the 
number of detectable autoantibodies (Fig.4). 
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Figure 4. Circulating levels of sICAM-1 (a) and sL-selectin (b), by the number of autoantibodies, in 208 
schoolchildren.  Each box-plot represents the median and the 25th and 75thper centiles.  The error bars represent the 
smallest and largest values that are not outliers. Ab indicates antibody. 
 
5.4 Relation of soluble adhesion molecules to insulin secretory capacity 
(I, III) 
There were no significant differences in the mean circulating concentrations of sICAM-1 and sL-selectin 
in the first sample taken at the beginning of the follow-up between the siblings with a reduced FPIR in 
their first IVGTT and those with a normal FPIR [sICAM-1 316 (65) μg/l (n=13) vs 282 (91) μg/l (n=35); 
p=0.223, and sL-selectin 2760 (780) μg/l (n=12) vs 2770 (1040) μg/l (n=36); p=0.980]. 
 50
No relationship was observed between median sICAM-1 levels and FPIR values in the autoantibody-
positive schoolchildren (data not shown), but those who had FPIR values under the 5th percentile (n=11) 
had significantly higher median sL-selectin levels than those with normal FPIR values: 2.27 mg/l [IQR 
1.69-2.71] mg/l vs 1.78 mg/l [1.44-2.14] mg/l; (p=0.026), and the same held true for those with FPIR 
values under the 10th percentile (n=17): 2.16 mg/l [1.73-2.46] mg/l vs 1.75 mg/l [1.43-2.08] mg/l; 
(p=0.009) (Fig.5). 
 
 
 
 
 
Figure 5. Circulating levels of sL-selectin in autoantibody-positive schoolchildren with a decreased FPIR (filled 
squares), i.e. <52.1 mU/l, the 10th percentile in the controls, compared with those with a normal FPIR (open circles).  
The regression line denotes the correlation between sL-selectin and age (sL-selectin=3.05-0.086 x age, r=0.40, 
p<0.001).  The subjects with a decreased FPIR had significantly higher sL-selectin concentrations than those with a 
normal FPIR (p=0.009).  The arrows mark the two children who subsequently progressed to overt type 1 diabetes. 
 
5.5 Follow-up of soluble adhesion molecules during the preclinical phase 
of type 1 diabetes (I, II, III, IV) 
5.5.1 Siblings of affected children (I, II) 
Those siblings who progressed to clinical type 1 diabetes during the observation had higher sICAM-1 
levels than the non-progressors in the first sample taken at the beginning of the follow-up, the mean 
(SD) levels being 313 (66) µg/l vs 260 (72) µg/l; p<0.001. This difference remained significant after 
adjustment for age (p=0.03). No significant difference in sL-selectin concentrations was seen between 
the progressors and non-progressors [2880 (880) µg/l vs 2700 (960) µg/l; p=0.40]. 
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No conspicuous general pattern in sICAM-1 or sL-selectin concentrations was seen during the 
follow-up among the progressors or non-progressors (Fig.6). Considerable fluctuations in the 
concentrations were observed in both groups. The peak levels of both adhesion molecules and the time 
points at which the levels peaked during the follow-up varied individually among both groups.  
No significant difference in total integrated concentrations of sICAM-1 existed between the 
progressors and non-progressors, but AUCICAM-1 was significantly higher in the progressors 6-48 months 
before the diagnosis of type 1 diabetes (p=0.035) (Table 6). The difference in the levels of sICAM-1 
between the groups was most conspicuous 18-24 months before diagnosis (p=0.015) (Fig.6). The 
integrated concentrations of sL-selectin over the total observation period were comparable in both 
groups (data not shown). 
 
 
 
 Figure 6. Circulating concentrations of soluble ICAM-1 in 39 autoantibody-positive progressors vs non-
progressors with preclinical type 1 diabetes.  Each box-plot represents the median and the 25th and 75th 
percentiles.  The bars represent the minimum and maximum values except for the outliers.  The figures above 
the x-axis refer to the number of siblings available in the two groups for each time interval.  Solid boxes 
represent the progressors and open boxes the non-progressors.
 
Nadir concentrations of sICAM-1 during the follow-up were significantly higher in the progressors 
among the ICA-positive siblings and tended to be higher in the progressors among the siblings positive 
for any of the other autoantibody specificities. Similarly, the progressors among the siblings with two or 
more autoantibodies initially or during the follow-up had higher nadir concentrations of sICAM-1 than 
the non-progressors (Table 6). We did not find any associations between sL-selectin nadir or peak 
concentrations and the various autoantibody specificities among the siblings. (data not shown).  
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Table 6. Circulating concentrations of sICAM-1 in siblings (n=4-39) of affected children who progressed to 
clinical type 1 diabetes during observation for a median period of 10 year and in unaffected siblings (n=11-
39).Ab indicates antibody. 
Progressors  Non-progressors  p-value 
Total AUC (μg months/l) 10464; 7214, 13177 (n=30) 9110; 5807, 12370 (n=30)  0.287 
AUC 48-6 months before diagnosis 7634; 4420, 9316 (n=24) 4527; 2890, 7435 (n=24)  0.035 
(μg months/l) 
Nadir concentration (μg/l)     256; 212, 303 (n=39)     213; 185, 274 (n=39)  0.058 
- ICA-positive      262; 218, 303 (n=35)     212; 180,268 (n=28)  0.009 
- ICA-negative      211; 197, 329 (n=4)     258; 199, 358 (n=11)  0.794 
- GADA-positive      247; 210, 300 (n=34)     210; 189, 265 (n=21)  0.066 
- GADA-negative      263; 227, 338 (n=5)     239; 183, 287 (n=18)  0.205 
- IAA-positive      250; 211, 304 (n=30)     212; 178, 262 (n=26)  0.071 
- IAA-negative      256; 214, 312 (n=9)     239; 194, 288 (n=13)  0.404 
- IA-2A-positive      243; 210, 299 (n=33)     210; 181, 257 (n=13)  0.059 
- IA-2A-negative      283; 216, 329 (n=6)     239; 191, 284 (n=26)  0.148 
- > 2 abs in the 1. sample     262; 210, 299 (n=29)     207; 180, 252 (n=12)  0.039 
- > 2 abs during the follow-up     249; 212, 302 (n=36)     207; 177, 239 (n=20)  0.003 
 
Peak concentration (μg/l)     355; 280, 432 (n=39)     347; 290, 403 (n=39)  0.374 
- ICA-positive      355; 319, 434 (n=35)     344; 298, 395 (n=28)  0.162 
- ICA-negative      303; 206, 366 (n=4)     361; 280, 406 (n=11)  0.267 
- GADA-positive      348; 277, 434 (n=34)     345; 298, 404 (n=21)  0.591 
- GADA-negative      361; 299, 394 (n=5)     355; 251, 380 (n=18)  0.628 
- IAA-positive      360; 336, 434 (n=30)     350; 282, 405 (n=26)  0.158 
- IAA-negative      280; 249, 367 (n=9)     343; 293, 371 (n=13)  0.217 
- IA-2A-positive      346; 265, 428 (n=33)     329; 307, 409 (n=13)  0.583 
- IA-2A-negative      367; 341, 434 (n=6)     350; 285, 371 (n=26)  0.201 
- > 2 abs in the 1. sample     346; 261, 421 (n=29)     346; 316, 405 (n=12)  1.000 
- > 2 abs during the follow-up     353; 272, 433 (n=36)     337; 298, 391 (n=20)  0.194 
 
5.5.2 Schoolchildren (III) 
The circulating concentrations of sL-selectin were higher in the progressors than in the non-progressors 
among the schoolchildren: 2.78 mg/l vs 1.79 mg/l (p<0.05), but this difference disappeared after 
adjustment for age (analysis of covariance after logarithmic transformation of the sL-selectin levels). 
The progressors among the subjects with three or more autoantibodies (n=7) had significantly higher sL-
selectin concentrations than the non-progressors: 2.78 mg/l vs 1.77 mg/l (p=0.04), without any 
significant age difference. 
5.5.3 Young children with HLA-DQ-conferred susceptibility to type 1 diabetes (IV) 
5.5.3.1 Soluble adhesion molecules in relation to autoantibodies 
The young genetically susceptible children had significantly lower concentrations of sICAM-1 and sL-
selectin in their cord blood than in later samples, the medians [25th and 75th percentiles IQR] being 155 [
134,182] μg/l vs 314 [269,368] μg/l (p<0.001) for sICAM-1 and 1.14 [0.93,1.31] mg/l vs 2.28 [
2.00,2.65] mg/l (p<0.001) for sL-selectin, but the concentrations were of the same magnitude in the 
cases and controls. The total integrated concentrations of sICAM-1 correlated with those of sL-selectin 
(rs=0.37, p<0.001). 
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There was no general pattern in the course of the circulating concentrations of sICAM-1 or sL-
selectin during the first 2 years of life among the children seroconverting autoantibody-positive by the 
age of 4 years or the control children remaining autoantibody-negative, and considerable fluctuations 
were seen in both groups. The concentrations of sICAM-1 and sL-selectin by age are presented in Fig.7. 
 
 
 
 
 
Figure 7. Serum concentrations of soluble ICAM-1 (A) and soluble L-selectin (B) over the first 2 years of life in 65 
young children who tested positive for ICA at least once before their fourth birthday vs 65 autoantibody-negative 
control children.  Each box-plot represents the median and the 25th and 75th percentiles. Solid boxes represent the 
cases and open boxes the controls.  The bars represent the minimum and maximum values except for outliers.  The 
figures above the x-axis refer to the number of children available in the two groups for each time interval. 
 
The total integrated concentrations were comparable between the autoantibody-positive and negative 
children (Table 7), and the children with two or more autoantibodies detected during the follow-up had 
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concentrations similar to those observed in the children with less than two autoantibodies. The children 
(n=32) with three or more autoantibodies detected during the follow-up likewise had concentrations 
similar to those seen in the children with a maximum of two autoantibodies (data not shown). The 
children (n=38) with multiple autoantibodies in the first ICA-positive sample had integrated 
concentrations of soluble adhesion molecules similar to those seen in the other autoantibody-positive 
children (data not shown). 
The children who seroconverted to positivity for ICA during the follow-up had higher integrated 
concentrations of sICAM-1 between 6 and 12 months of age than those who remained negative for ICA 
(Table 8), and those who seroconverted to positivity for IA-2A during the follow-up had higher 
integrated concentrations of sL-selectin during the second half of the first year of life than those who 
remained autoantibody-negative (Table 9). We did not find any differences between the ICA or IA-2A-
positive converting children and those remaining seronegative with respective to the duration of 
exclusive or total breast-feeding or the age at introduction of cow’s milk. No associations were seen 
between the concentrations of soluble adhesion molecules and IAA or GADA positivity.  
 
 
Table 7. Circulating concentrations of sICAM-1  and sL-selectin during the first 2 years of life in young children 
testing positive for at least one autoantibody before their fourth birthday vs control children.  The values are 
medians; 25th, 75th percentiles. 
AUC (mg days/l) Autoantibody-positive Autoantibody-negative  p-value 
Total AUCICAM-1  220; 196,259(n=65) 221; 192,247(n=65)  1.00 
Total AUCL-selectin 1600; 1410,1810(n=65) 1600; 1380,1880(n=65)   1.00 
AUC(6-12 mo)ICAM-1 54; 48,65(n=56) 50; 45,60(n=56)  0.23 
AUC(6-12 mo)L-selectin 439; 372,481(n=56) 401; 341,464(n=56)    0.25 
 
Table 8. Circulating concentrations of sICAM-1 and sL-selectin in young children testing positive for ICA during 
the follow-up vs control children remaining negative for ICA.  The values are medians; 25th, 75th percentiles. 
AUC (mg days/l) ICA-positive   ICA-negative   p-value 
Total AUCICAM-1 228; 203,263(n=58) 218; 182,243(n=72)  0.24 
Total AUCL-selectin 1600; 1420,1800(n=58) 1600; 1380,1850(n=72)  1.00 
AUC(6-12 mo)ICAM-1 55; 48,66(n=48) 50; 44,60(n=64)  0.07 
AUC(6-12 mo)L-selectin 441; 374,481(n=48) 401; 341,464(n=64)  0.26 
 
Table 9. Circulating concentrations of sICAM-1 and sL-selectin in young children testing positive for IA-2A 
during the follow-up vs control children remaining negative for IA-2A.  The values are medians; 25th, 75th 
percentiles. 
AUC (mg days/l) IA-2A-positive  IA-2A-negative  p-value 
Total AUCICAM-1 228; 195,268(n=20) 220; 195,247(n=110)  1.00 
Total AUCL-selectin 1740; 1530,1880(n=20) 1560; 1390,1820(n=110)  0.23 
AUC(6-12 mo)ICAM-1 50; 44,65(n=16) 53; 46,63(n=96)  1.00 
AUC(6-12 mo)L-selectin 466; 425,481(n=16) 406; 348,469(n=96)  0.07 
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There was no striking general pattern in the course of either sICAM-1 or sL-selectin among the 21 
children [median age of seroconversion 12 months (range 3-27 months)] who progressed to clinical 
diabetes, and they had integrated concentrations of soluble adhesion molecules similar to those seen in 
the other autoantibody-positive children, the other children with two or more autoantibodies (n=19) and 
the control children (data not shown).  
The autoantibody-positive children had higher sL-selectin concentrations in the 3-month period 
during which seroconversion to autoantibody positivity occurred than did the control children in the 
same period of time (Fig.8). No significant difference was seen between the cases and controls over the 
preceding or following 3-month periods. The median concentrations of sICAM-1 were similar in the 
cases and controls during the 3-month seroconversion period: 326 [271,387] μg/l (n=57) vs 306 
[265,346] μg/l (n=55) (p=0.061). No difference in the median concentrations of soluble adhesion 
molecules during the 3-month seroconversion period was seen between those children who presented 
with type 1 diabetes by the age of 5 years (all of them positive for two or more antibodies during the 
follow-up) and the other autoantibody-positive children with two or more antibodies, or between those 
positive for ICA only and those initially seroconverting to positivity for one or more autoantibodies in 
addition to ICA (data not shown). 
 
 
 
Figure 8. Serum concentrations of soluble L-selectin over the 3-month periods preceding, coinciding with and 
following seroconversion (SC) in children converting to positivity for any autoantibody and during the corresponding 
periods in the control children remaining negative for all autoantibodies. Each box-plot represents the median and 
the 25th and 75th percentiles. Solid boxes represent the cases and open boxes the controls. The bars represent the 
minimum and maximum values except for outliers. n refers to the number of children available in both groups during 
each time interval.  
 
 56
5.5.3.2 Soluble adhesion molecules in relation to enterovirus infection 
The median levels of sL-selectin were higher in the 3-month period after which an enterovirus infection 
was verified than in the previous and subsequent 3-month periods in the autoantibody-positive children 
(p=0.002), but not in the control children (p=0.071). The children who seroconverted to autoantibody 
positivity had higher sL-selectin concentrations in the time interval during which an enterovirus 
infection was diagnosed than did the autoantibody-negative children during the corresponding time 
interval [2.53 (2.22,2.68) mg/l vs 2.28 (1.94,2.47) mg/l; p=0.006]. The median concentrations of sL-
selectin were also higher during this period in the children who seroconverted to positivity for IA-2A 
during the follow-up than in those who remained autoantibody-negative: 2.55 [2.46,2.71] mg/l (n=16) vs 
2.31 [1.99,2.54] mg/l (n=39) (p=0.004). The median age at which an enterovirus infection was detected 
did not differ between the groups: median 12 months (range 9-24 months) for the IA-2A-positive 
children and median 12 months (range 6-24 months) for the IA-2A-negative control children.  
The differences were no longer significant after exclusion of those children who seroconverted to 
autoantibody positivity during the interval with a concomitant enterovirus infection. A multiple 
regression analysis with the circulating concentrations of sL-selectin as the dependent variable and 
seroconversion to autoantibody positivity and enterovirus infections as independent variables showed 
that sL-selectin levels in the peripheral circulation were associated with seroconversion to autoantibody 
positivity (β=0.29; p=0.017) but not with enterovirus infections (β=0.09; p=0.47). 
5.5.3.3 Soluble adhesion molecules in relation to diet in early infancy  
We did not find any correlation between the integrated concentrations of ICAM-1 from 6 to 12 months 
and the duration of exclusive or total breast-feeding or age at introduction of cow’s milk among the 
children who eroconverted to ICA positivity during the follow-up. Nor did we find any correlation 
between the integrated concentrations of sL-selectin from 6 to 12 months and the duration of exclusive 
or total breast-feeding or age at introduction of cow’s milk among the children who seroconverted to IA-
2A positivity during the follow-up (data not shown). 
Total integrated sL-selectin concentrations among the progressors presenting with clinical diabetes 
by the age of 5 years tended to be inversely related to the age at the introduction of cow’s milk (rs=-0.40, 
p=0.071, n=21) and also to the duration of exclusive breast-feeding (rs=-0.31, p=0.17, n=21), although 
the correlations remained non-significant. Among the progressors with clinical type 1 diabetes 
diagnosed after the age of 3 years, the total integrated sL-selectin concentrations were inversely related 
to the age at which cow’s milk was introduced (rs=-0.74, p=0.037, n=8), and there was also a tendency 
for an inverse relationship between total integrated concentrations of sICAM-1 and the duration of 
overall breast-feeding (rs=-0.66, p=0.076, n=8). Inverse relationships were observed between integrated 
concentrations of sICAM-1 during the period 6-12 months and age at the introduction of cow’s milk 
(rs=-0.75, p=0.052, n=7), the duration of exclusive breast-feeding (rs=-0.75, p=0.052, n=7) and that of 
overall breast-feeding (rs=-0.86, p=0.012, n=7), and this was also true of the integrated concentrations of 
sL-selectin over the period from 6 to 12 months and age at the introduction of cow’s milk (rs=-0.75, 
p=0.052, n=7), and the duration of exclusive breast-feeding (rs=-0.75, p=0.052, n=7), while the 
correlation with overall breast-feeding remained non-significant (rs=-0.59, p=0.16, n=7). 
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6 Discussion 
6.1 Soluble adhesion molecules in relation to HLA risk markers 
The genetic determinants of soluble adhesion molecule levels are largely unknown. A trend was 
observed here for lower sICAM-1 and sL-selectin concentrations in antibody-negative siblings with the 
HLA-DR3/non-DR4 phenotype than in those who were heterozygous for DR3/4 or carried the DR4/non-
DR3 or non-DR3/non-DR4 combinations, but the difference remained non-significant for both. DR3 
patients have been observed to present with a milder disease at diagnosis than those with DR3/4 or DR4, 
having ketonuria or ketoacidotic symptoms less often and showing a subsequent partial remission more 
often (Ludvigsson et al. 1986). 
In line with the present observations, Lampeter et al. (1992) did not observe any significant 
differences in the circulating concentrations of sICAM-1 or sL-selectin between healthy blood donors 
(n=100) with or without HLA-DR3 and/or DR4 risk alleles. On the other hand, we observed increased 
levels of sL-selectin in autoantibody-negative schoolchildren representing the general population who 
had the HLA-DQB1 genotypes associated with a low or decreased risk of type 1 diabetes, although we 
did not find any association between soluble adhesion molecules and specific HLA-DQB1 alleles 
conferring either protection against (DQB1*0602, *0301) or susceptibility to type 1 diabetes 
(DQB1*0302, *02), suggesting that the increased sL-selectin concentrations are not associated with any 
specific HLA-DQB1 allele. In contrast, Krętowski et al. (2000a) reported a positive relationship between 
high levels of sL-selectin and the presence of HLA alleles conferring a high risk of clinical type 1 
diabetes, i.e. DR3/4 or DQB1*0201/*0302 (n=3), among healthy adult controls of Polish origin. 
Intermediate high levels were seen in subjects with either the DR4-DQB1*0302 or the DR3-
DQB1*0201 haplotype without the DQB1*0602 allele (n=21), and intermediate low levels in subjects 
with either the DR4-DQB1*0302 or DR3-DQB1*0201 haplotype in combination with the DQB1*0602 
allele (n=11). The lowest concentrations were observed in those with a genotype comprising none of the 
high-risk alleles (n=23).  
The conflicting results are difficult to explain, but the number of subjects investigated so far has been 
low, especially the number of individuals carrying high-risk genotypes, which increases the likelihood 
of chance findings. Polymorphism in the L-selectin gene has been implicated as being able to modulate 
circulating sL-selectin levels. The presence of the T668C mutation in the L-selectin gene located on the 
long arm of chromosome 1 was associated with lower levels of circulating sL-selectin in a subgoup of 
unaffected relatives, but also in healthy controls, relative to the concentrations observed in subjects 
without this mutation. Since the T668C mutation was associated with HLA-DQ-conferred protection 
against diabetes in unaffected relatives but not in patients with diabetes or in unrelated control subjects, 
it was thought to play a protective role in the development of type 1 diabetes (Krętowski et al. 2000a). 
The group headed by Krętowski and Kinalska (2000b) later confirmed in a larger series that unaffected 
first-degree relatives have a higher frequency of the L-selectin gene T668C mutation than do the 
probands themselves or healthy controls, as 45 unaffected first-degree relatives out of the 72 analysed 
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(63%) had the T668C mutation, while the corresponding proportion among relatives with type 1 
diabetes was 32% (29/91) and that among the controls 38% (31/81). Further analysis showed that the 
highest frequency of the T668C mutation was seen in first-degree relatives with the protective HLA-
DQB1*0602 allele (17/21; 81%) and the non-DR3/non-DR4 phenotype (4/6), while the frequency of 
this mutation was similar among the first-degree relatives with the high-risk DR4-DQB1*0302 
haplotype and among controls. Based on these results, it was suggested that the T668C mutation could 
have an influence on soluble L-selectin levels and potentially provide protection from progression to 
type 1 diabetes.  
6.2 Soluble adhesion molecules in relation to autoantibodies 
The question of a relationship between the levels of soluble adhesion molecules and various 
autoantibody specificities has remained controversial in the family studies conducted so far. Myśliwiec 
et al. (1999) reported positive correlations between sICAM-1 concentrations and ICA titres (rs=0.47), 
GADA titres (rs=0.45) and the number of autoantibodies (rs=0.56) in 26 first-degree relatives (mean age 
21.0 ± 8.1 years) with ICA > 20 JDFU, whereas Lampeter et al. (1992) did not find any clear association 
between the circulating concentrations of soluble adhesion molecules and ICA positivity in 33 first-
degree relatives (six positive for ICA) of patients with type 1 diabetes, nor did Krętowski et al. (2000a) 
observe any difference in the levels of sL-selectin between subjects without autoantibodies and subjects 
with one or more autoantibodies or with two or more autoantibodies in a series of 90 first-degree 
relatives, of whom 50 tested positive for at least one autoantibody (ICA, GADA, IAA and/or IA-2A).  
We found no differences in the concentrations of soluble adhesion molecules between the 
autoantibody-positive and negative children, either among the siblings of children with type 1 diabetes 
or among those derived from the general population. These observations are in line with the findings of 
Krętowski et al. and Lampeter et al. suggesting that beta-cell autoimmunity per se is not associated with 
elevated levels of soluble adhesion molecules, i.e. markers of endothelial and leukocyte activation. The 
siblings with an ICA level of 20 JDFU or more in their initial sample had higher sICAM-1 
concentrations than those with a lower titre, and 62% (23/37) of these had progressed to clinical type 1 
diabetes by the end of 1997. An ICA level of 20 JDFU or more has been observed to be highly 
predictive of progression to clinical disease in the DiMe series of siblings of children with type 1 
diabetes (Knip et al. 1998), and a positive association between the risk of progression and the ICA titre 
has been demonstrated extensively among first-degree relatives, and is also implied in the background 
population (Karjalainen et al. 1990). We could not, however, confirm the association between high titres 
of ICA and increased concentrations of sICAM-1 in the present series of schoolchildren, although a 
tendency towards higher levels of circulating sICAM-1 was seen in subjects with an ICA level of 40 
JDFU or more. Two out of 15 schoolchildren with an ICA titre of 40 JDFU or more progressed to 
clinical type 1 diabetes during a follow-up of an average of 3.4 years, which is substantially less than 
would be expected among siblings. The positive PPV reported for type 1 diabetes development 
associated with an ICA titre of 40 JDFU or more was 58% in the DiMe sibling series over a time period 
of 7.7 years (Kulmala et al. 1998). Taken together, these observations suggest that ICA positivity is 
associated with increased circulating concentrations of sICAM-1 when it reflects a substantially 
increased risk of progression to clinical type 1 diabetes. 
IA-2A appear relatively late in the prediabetic phase and reflect a high risk of progression to clinical 
disease (Christie et al. 1997, Knip et al. 1998). Their emergence is associated with rapid progression to 
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overt diabetes (Bingley et al. 1994, Christie et al. 1994, Gardner et al. 1999). We observed a positive 
association of high sICAM-1 and sL-selectin concentrations with IA-2A positivity in siblings. 
Moreover, IA-2A titres were related to increased sICAM-1 concentrations in the peripheral circulation 
in schoolchildren who were positive for IA-2A. The association between sICAM-1 concentrations and 
IA-2A levels after seroconversion is interesting, since a direct correlation has been demonstrated 
between humoral and cellular immune responses to the IA-2 autoantigen, confirming the role of the 
latter in the pathogenesis of type 1 diabetes, where cellular mechanisms are most likely the principal 
mediators of beta-cell destruction (Ellis et al. 1998). 
Positivity for multiple autoantibodies indicates a high risk of progression to overt diabetes, and also 
appears to be associated with accelerated beta-cell destruction and increased requirements for exogenous 
insulin over the second year of the clinical disease (Sabbah et al. 1999). Multiple autoantibodies have 
been reported to have a substantially higher predictive value for type 1 diabetes in a series of family 
studies than positivity for a single antibody (Bingley et al. 1994, Verge et al. 1996, Kulmala et al. 1998). 
Furthermore, recent observations on subjects derived from the general population support the concept 
that multiple autoantibodies are also good predictive markers of type 1 diabetes in the general 
population (Maclaren et al. 1999, Kimpimäki et al. 2000, Kulmala et al. 2001, LaGasse et al. 2002). 
Multiple autoantibodies have been reported to be more prevalent in subjects with the high-risk HLA 
genotype than in those with other genotypes (Kulmala et al. 2000b), and the HLA-DQB1 genotypes 
indicating high or moderate risk were also more frequent among the children with multiple 
autoantibodies in our series of schoolchildren (8/16) than in the children positive for only one 
autoantibody (8/88). In the family study we observed higher concentrations of sICAM-1 and sL-selectin 
in siblings with three or more autoantibodies in their initial sample than in those with a maximum of two 
autoantibodies, and proposed that positivity for three or more antibodies could reflect an on-going 
destructive immune process in the pancreatic islets. Only six out of the cohort of 29 subjects progressing 
to clinical type 1 diabetes during observation for an average of 7 years tested positive for one or two 
autoantibodies in their initial sample, while 23 had three or four autoantibodies. Contrary to our 
expectations, we could not confirm any association between high levels of soluble adhesion molecules 
and positivity for multiple autoantibodies in the general population. It is plausible that the autoimmune 
process may be milder in such a population than in siblings of affected children, possibly reflecting 
slower progression to clinical disease, and therefore no concomitant increase in the circulating 
concentrations of soluble adhesion molecules would be seen. Based on the degree of insulitis and 
proportion of insulin deficient islets in the pancreas in patients with recent-onset type 1 diabetes, an age-
related heterogeneous course of the disease has been suggested (Foulis et al. 1986). On-going insulitis 
has been found in an anti-GAD65-positive adult patient with residual beta-cell function (Shimada et al 
1999), further suggesting slowly progressing beta-cell destruction in older subjects.  
Although the discrepancies in the present results may be due to the heterogeneous course of 
preclinical type 1 diabetes and different stages of autoimmunity, they are more likely to indicate that the 
concentrations of soluble adhesion molecules only partly overlap with traditional markers of an active 
autoimmune process, i.e. autoantibodies against islet cell antigens. They may reflect different 
characteristics of the autoimmune process from the conventional humoral immune markers, although 
intra-individual and inter-individual variation is substantial, suggesting that other, unrelated factors have 
a major impact on the circulating concentrations.  
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6.3 Soluble adhesion molecules in relation to impaired beta-cell function 
Beta-cell function can be assessed from the insulin response to intravenous glucose to serve as an 
indirect measure of the remaining beta-cell mass. A reduced FPIR is highly predictive of rapid 
progression to overt type 1 diabetes in relatives of affected patients with multiple autoantibodies 
(Bingley et al. 1996), and progressive loss of beta-cell function has been observed a matter of months to 
years prior to the diagnosis of clinical diabetes (Srikanta et al. 1983). Early beta-cell failure soon after 
seroconversion to autoantibody positivity has recently been reported in young genetically susceptible 
children in the general population (Keskinen et al. 2002). On the other hand, subclinical and non-
progressive (or very slowly progressive) beta-cell dysfunction has also been reported (Greenbaum et al. 
1999). At least some of the impairment in insulin secretion may be functional, due to the inhibition of 
insulin secretion by cytokines and other soluble factors, as implied by Mehta et al. (1994).  
Increased circulating concentrations of sL-selectin in autoantibody-positive schoolchildren with 
signs of impairment in their insulin secretory capacity may reflect activation of the leukocytes involved 
in an active process of insulitis. We were unable to observe any association between a reduced FPIR 
value (<45 mU/l) and circulating levels of soluble adhesion molecules in the sibling series, but the 
controversial results are most likely to be explained by differences in the timing of sampling in relation 
to the IVGTT, as the concentrations of soluble adhesion molecules were measured from the fasting 
IVGTT sample in the cohort of schoolchildren, whereas those in the series of siblings of affected 
children were analysed in the first sample taken close to the diagnosis of the index case, the IVGTT 
being performed on average of 6 months later.  
6.4 Soluble adhesion molecules in the course of prediabetes 
L-selectin plays a major role in the first two steps in the lymphocyte homing process, tethering and 
rolling (Springer 1990, von Andrian and Mackay 2000), but is also involved in the priming process of 
naïve T cells, which differentiate into antigen-specific armed effector T cells after having encountered 
an antigen. Many T cells lose their expression of L-selectin during this process. We observed elevated 
concentrations of circulating sL-selectin in the 3-month period preceding the detection of the first 
autoantibody in children with increased HLA-conferred susceptibility to type 1 diabetes, suggesting 
enhanced leukocyte activation, which may reflect a lymphocyte homing process and/or T-cell activation 
at the stage of the initiation of beta-cell autoimmunity. On the other hand, the children who 
seroconverted to autoantibody positivity by the age of four, and even those who presented with multiple 
autoantibodies during the follow-up or with the clinical disease by the age of five, did not have increased 
integrated levels of soluble adhesion molecules during their first two years of life, implying that early-
onset beta-cell autoimmunity – even with rapid progression to clinical diabetes - is not accompanied by 
signs of general endothelial/leukocyte activation in the peripheral circulation. The randomized 
intervention trial with nasal insulin for the children in the DIPP cohort with persistent autoantibody 
positivity is likely to have had a minimal impact on the present results, since only ten of the 65 positive 
children had been randomized for the placebo-controlled double-blind trial by the end of the follow-up. 
The intervention was initiated at a mean age of 18.3 months (range 15-21 months) in the ten 
participants, and its mean duration during the follow-up was 6.6 months (range 3-9 months). 
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We did find elevated levels of sICAM-1 at the age of 6-12 months in the children belonging to the 
DIPP cohort who seroconverted to positivity for ICA before their second birthday, which may indicate 
the importance of this period for the initiation of beta-cell autoimmunity in young children. Increased 
levels of sICAM-1 at the age of 3, 6, 9 and 12 months have been reported earlier in infants who received 
cow’s milk-based formula as compared with those observed in infants fed with a highly hydrolyzed 
formula until the age of 9 months (Paronen et al. 1996). There is increasing evidence in both man and 
rodents that the gut-associated immune system plays a major role in the development of autoimmune 
diabetes, probably because of disturbed development of oral tolerance, which is dependent on 
immunological homeostasis and normal maturation of the gut (Harrison and Honeyman 1999, Vaarala 
1999). These are in turn influenced by growth factors and cytokines from breast milk, normal bacterial 
colonization, infections and diet, all of which are implicated as potential risk factors for type 1 diabetes. 
As the induction of adaptive immune functions, including oral tolerance, seems to be an age-dependent 
phenomenon in young children (Vaarala et al. 1995), there may be a critical window for the exposure of 
children prone to type 1 diabetes to dietary antigens in relation to weaning. This is also indicated by a 
recent study on the association between gluten exposure and the risk of the appearance of autoantibodies 
in infants with a HLA-defined predisposition to type 1 diabetes (Norris et al. 2003). The development of 
oral tolerance may also be influenced by other environmental exposures such as the establishment of a 
normal bacterial flora and viral infections, the rate of which increases drastically during the second half 
of the first year of life, as transplacentally transferred maternal IgG levels decrease gradually during the 
first 6 months.  
Breast-feeding has been reported to have positive effects on the postnatal maturation of the immune 
system, e.g. the CD4/CD8 lymphocyte subset ratio has been observed to be lower in breast-fed infants 
than in formula-fed ones (Hawkes et al. 1999). Those eight children who progressed to clinical diabetes 
after the age of 3 years showed a relatively close inverse correlation between circulating concentrations 
of sICAM-1 and sL-selectin, particularly at 6-12 months of age, and both age at the introduction of 
cow’s milk-based formula and the duration of exclusive and overall breast-feeding. This may be due to 
enhanced immune activation in infants of that age, induced by increased exposure to foreign dietary 
proteins, as proposed in an earlier report (Paronen et al. 1996), and indicates that early introduction of 
cows’ milk or other foreign antigens and/or short duration of breast-feeding is associated with a 
proinflammatory state, predisposing young children who have an increased genetic risk of type 1 
diabetes to a process of beta-cell destruction. 
Enterovirus infections have also been reported to be temporally associated with the emergence of 
diabetes-associated autoantibodies, suggesting that they may trigger beta-cell autoimmunity (Lönnrot et 
al. 2000). We observed higher circulating concentrations of sL-selectin in association with enterovirus 
infections in those children who seroconverted positive for autoantibodies than in the control subjects. 
This difference became non-significant, however, after the exclusion of those cases who seroconverted 
to autoantibody positivity concomitantly with an enterovirus infection. A multiple regression analysis 
implied that increased sL-selectin levels were associated with seroconversion to autoantibody positivity 
but not with signs of an enterovirus infection. Altogether, these observations suggest that the transiently 
increased circulating sL-selectin concentrations seen in this cohort are related to the appearance of beta-
cell autoimmunity rather than to enterovirus infections.  
Inverse seroconversions were rarely seen in the IA-2A-positive cases in this cohort of young 
children, and of the individual autoantibodies, IA-2A had the highest specificity (100%) and a PPV of 
92% for persistent multiple autoantibody positivity by the age of 2 years, indicating that they are 
markers of aggressive, rapidly progressing beta-cell autoimmunity (Kimpimäki et al. 2002). The 
children seroconverting to IA-2A positivity during the follow-up showed especially high integrated 
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concentrations of sL-selectin at the age of 6-12 months, and 14 out of these 16 children seroconverted to 
autoantibody positivity (for any autoantibody) during this period. The increased concentrations of sL-
selectin at the age of 6-12 months in children developing signs of progressive beta-cell autoimmunity by 
the age of two years may imply that seroconversion during this period could be critical.  
There was no obvious trend for increasing concentrations of soluble adhesion molecules towards 
diagnosis of the clinical disease among the children representing familial type 1 diabetes and presenting 
with autoantibodies at the beginning of the follow-up. A German survey has reported that the peripheral 
concentrations of sICAM-1 and sL-selectin were increased to approximately the same extent both in 
patients with recently diagnosed type 1 diabetes and in healthy first-degree relatives irrespective of 
autoantibody status or HLA-DR risk alleles (Lampeter et al. 1992). A similar observation regarding sL-
selectin was reported by Krętowski et al. (2000a), who found no significant difference between patients 
with newly diagnosed type 1 diabetes and first-degree relatives (autoantibody-positive or negative), 
although both of them had increased levels relative to healthy controls. They observed no correlation 
between sL-selectin levels and HbA1c or blood glucose concentrations, indicating that hyperglycaemia 
does not lead to increased sL-selectin levels. The sL-selectin concentrations did not differ between the 
controls and patients with either type 2 or type 1 diabetes for more than 10 years (Krętowski et al. 
2000a). In another study the levels of sICAM-1 were found to be higher in non-diabetic first-degree 
relatives with an ICA level of 20 JDFU or more than in age and sex-matched unrelated healthy controls, 
and even higher than in patients with newly diagnosed type 1 diabetes (Myśliwiec et al. 1999).  
Although the source and physiological function of sICAM-1 remains to be established, increased 
levels in progressors over a 3.5 year period in the preclinical phase may reflect endothelial and 
leukocyte activation due to destructive insulitis, being most prominent about 1.5 years before diagnosis. 
This observation is in line with evidence from both in vitro and in vivo studies that suggest a role for 
ICAM-1-driven Th1 polarization (Samoilova et al. 1998, Arai et al. 1999, Balasa et al. 2000, Smits et al. 
2002). A Th1-dominated cytokine profile has been documented in subjects at risk for type 1 diabetes 
(Hussain et al. 1998, Karlsson et al. 2000). Alternatively we cannot rule out that sICAM-1 may be 
elevated due to a defensive attempt of the immune system to reduce aggressive insulitis. Recombinant 
ICAM-1 proteins (5 µg three times/a week for 4.5 months) beginning at age 35 days have been shown to 
inhibit insulitis and the onset of autoimmune diabetes in NOD mice (Martin et al. 1998). Recombinant 
soluble ICAM-1 has also been shown to suppress the reactivity of autoimmune T cells from recent-onset 
type 1 diabetic patients in response to an islet-specific autoantigen in concentrations found in subjects at 
risk for type 1 diabetes (Lampeter et al. 1992, Roep et al. 1994). 
We did not observe any increases in the total integrated concentrations of soluble adhesion 
molecules in the DiMe siblings, more than 80% of whom tested positive for one or more autoantibodies 
at the time of initial sampling. Neither was there any relationship between integrated soluble adhesion 
molecule concentrations and specific autoantibodies or the number of autoantibodies detected during the 
follow-up. This negative finding may be due to the limited number of cases in each group, but it is more 
likely to suggest that there are factors other than the autoimmune process which affect the levels of 
soluble adhesion molecules in the peripheral circulation. When observing separately the possible 
variation in nadir sICAM-1 levels in relation to different autoantibody specificities, a tendency was 
noted for higher levels in those who progressed to overt type 1 diabetes, although significantly so only 
among the ICA-positive siblings and the siblings with two or more autoantibodies detected in the initial 
sample or during the follow-up.   
We observed both among the autoantibody-positive siblings and among the young genetically 
susceptible children who seroconverted to autoantibody positivity during the follow-up that there were 
conspicuous intra-individual and inter-individual variation in the concentrations of soluble adhesion 
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molecules. This indicates that there are factors other than the diabetic disease process that affect the 
circulating concentrations of soluble adhesion molecules. Viral infections could modify these, and at 
least enteroviruses, respiratory syncytial virus (RSV) and human rhinoviruses have been reported to use 
ICAM-1 as their receptor (Racaniello 1995, Smyth et al. 1997, Van Kempen et al. 1999). In addition, 
RSV infections have been observed to increase the serum concentrations of soluble ICAM-1 (without 
any correlation with disease severity) in a series of children less than 1 year of age hospitalized for acute 
bronchiolitis (Smyth et al. 1997). Kulander et al. (2001) did not find any elevation in circulating 
sICAM-1 concentrations in 35 adult patients with evidence of viral infections, in contrast to 66 patients 
affected by bacterial infections. In the sibling cohort, we suggest that the impact of viral infections 
cannot be substantial, since the peak and total concentrations of sICAM-1 were similar in the siblings 
younger than 5 years of age and the older ones. One would also expect that the impact of viral infections 
would be the same in both progressors and non-progressors, although there are certain indications that 
immunological abnormalities related to the autoimmune process preceding the clinical manifestation of 
type 1 diabetes, such as depletion of memory CD4-positive cells and defective killer-cell activity, could 
transiently impair host defence against viral diseases in high-risk first-degree relatives (Moutschen et al. 
1992). In the DIPP cohort the effect of viral infections may have been more pronounced, since RSV 
infections are especially common in this age group (Tsai et al. 2001, van Woensel et al. 2003).   
In conclusion, although complex interactions between adhesion molecules are most likely to be 
involved in the initiation and propagation of autoimmune processes, such as type 1 diabetes, no specific 
or unique over-expression of adhesion molecules confined to any particular situation has been identified. 
This lack of specificity is reflected in the levels of soluble adhesion molecules reported in the present 
work, as any type of inflammatory or infectious process will utilize the adhesion cascade in a similar 
manner. Furthermore, the lack of standardization of ELISAs, i.e. the various specificities and standards 
used, may account for some discrepancies between the findings reported in different studies. Therefore 
the present assays available for measuring the concentrations of soluble adhesion molecules seem to be 
of limited diagnostic value in the context of preclinical type 1 diabetes. Similar conclusions have been 
drawn in relation to other autoimmune and inflammatory diseases as well.  
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7 Conclusions 
I. Type 1 diabetes-associated HLA class II alleles do not have a major impact on the circulating 
concentrations of sICAM-1, while HLA-DQB1 genotypes may modify sL-selectin 
concentrations in the peripheral circulation.  
 
 
II. Autoimmunity per se is not associated with elevated circulating concentrations of sICAM-1 or 
sL-selectin. Autoantibody markers with strong predictive value, i.e. multiple autoantibodies, high 
ICA levels and positivity for IA-2A, are related to increased levels of soluble adhesion molecules 
in familial type 1 diabetes, but not in non-familial cases. This indicates that these markers only 
partly overlap with conventional humoral immune markers, i.e. autoantibodies against islet cell 
antigens. They may reflect other characteristics of the autoimmune process, although intra-
individual and inter-individual variation is substantial, indicating that there are several other 
unrelated factors affecting the circulating concentrations.  
 
 
III. Increased concentrations of sL-selectin in subjects with impaired beta-cell function may reflect 
the leukocyte activation associated with on-going destructive insulitis. 
 
 
IV. Early-onset progressive beta-cell autoimmunity, or even progression to clinical type 1 diabetes 
by the age of 5 years, is not reflected in overall increased concentrations of soluble adhesion 
molecules in the peripheral circulation during the first 2 years of life in children with increased 
HLA-conferred disease susceptibility, although elevated concentrations of sL-selectin are 
temporally associated with seroconversion to autoantibody positivity.  
The older children representing familial type 1 diabetes presented with increased levels of 
sICAM-1 6-48 months before diagnosis, which may reflect immune activation and/or tissue 
destruction going on in progressors. Alternatively it may be a defensive attempt to reduce 
aggressive insulitis. The substantial overlapping in the circulating levels of soluble adhesion 
molecules between the progressors and non-progressors on all occasions implies, however, that 
peripheral sICAM-1 and sL-selectin concentrations cannot provide a clinically meaningful tool 
for identifying those children who will develop clinical type 1 diabetes.  
 
 
V. The increased levels of soluble adhesion molecules during the second half of the first year may 
reflect the importance of this age for the induction of early beta-cell autoimmunity in genetically 
susceptible children. Stronger immune activation due to exposure to dietary antigens during 
weaning, reflected in elevated concentrations of soluble adhesion molecules, may be detrimental 
in some children who manifest overt diabetes by the age of 5 years. 
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8 Summary 
The aim of this work was to characterize the active autoimmune process preceding the clinical 
manifestation of human type 1 diabetes, both familial and non-familial, based on the quantification of 
circulating concentrations of sICAM-1 and sL-selectin, which are established markers of endothelial and 
leukocyte activation. We also aimed at assessing whether these markers could be used to discriminate 
between disease progressors and non-progressors, in order to improve the prediction of type 1 diabetes 
on an individual basis in children and adolescents.  
We did not observe any relationship between sICAM-1 and HLA class II-conferred susceptibility to 
type 1 diabetes, but sL-selectin concentrations were higher in autoantibody-negative schoolchildren 
carrying HLA-DQB1 genotypes conferring low or decreased risk for type 1 diabetes. 
Autoimmunity per se is not associated with elevated concentrations of sICAM-1 or sL-selectin. 
Autoantibodies with strong predictive value, i.e. multiple autoantibodies, high ICA levels and positivity 
for IA-2A, are related to increased concentrations of soluble adhesion molecules in familial type 1 
diabetes, but not in non-familial cases, indicating that these markers only partly overlap with 
conventional humoral immune markers, i.e. autoantibodies against islet cell antigens. They may reflect 
other characteristics of the autoimmune process, although intra-individual and inter-individual variation 
is substantial, indicating that there are several other unrelated factors affecting the concentrations of 
soluble adhesion molecules in the peripheral circulation.  
Increased concentrations of sL-selectin in subjects with impaired beta-cell function may reflect 
leukocyte activation associated with destructive insulitis. 
Early-onset progressive beta-cell autoimmunity, or even progression to clinical type 1 diabetes by 
the age of 5 years, is not reflected in overall increased concentrations of soluble adhesion molecules in 
the peripheral circulation during the first 2 years of life in children with increased HLA-conferred 
disease susceptibility, although elevated concentrations of sL-selectin were found to be temporally 
associated with seroconversion to autoantibody positivity. The older children representing familial type 
1 diabetes presented with increased levels of sICAM-1 6-48 months before diagnosis, which may reflect 
immune activation and/or tissue destruction going on in the progressors. Alternatively it may be a 
defensive attempt to reduce aggressive insulitis. The substantial overlapping in the circulating levels of 
soluble adhesion molecules between the progressors and non-progressors on all occasions implies, 
however, that peripheral sICAM-1 and sL-selectin concentrations cannot provide a clinically meaningful 
tool for differentiating those children who will develop clinical type 1 diabetes from those who will 
remain non-diabetic. 
The increased levels of soluble adhesion molecules during the second half of the first year may 
reflect the importance of this age for the induction of early beta-cell autoimmunity in genetically 
susceptible children. The stronger immune activation due to exposure to dietary antigens in relation to 
weaning, reflected in increased concentrations of soluble adhesion molecules during this period, may be 
detrimental in some children who manifest overt diabetes by the age of 5 years. Soluble adhesion 
molecules do not seem to be helpful in identifying the environmental factors involved in the 
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pathogenesis of type 1 diabetes, since other non-specific factors, such as common viral infections, may 
have an impact on their concentrations in the peripheral circulation. 
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